var title_f8_31_8688="Traction bronchiectasis CT";
var content_f8_31_8688=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70396&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Postradiation traction bronchiectasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 298px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Traction bronchiectasis in a patient with Hodgkin's disease and previous mantle irradiation. The main finding is paramediastinal radiation fibrosis, with loss of volume and mild cylindrical bronchiectasis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_31_8688=[""].join("\n");
var outline_f8_31_8688=null;
var title_f8_31_8689="Normal rhythm strip";
var content_f8_31_8689=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F59022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F59022&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_31_8689=[""].join("\n");
var outline_f8_31_8689=null;
var title_f8_31_8690="Distal common bile duct stricture";
var content_f8_31_8690=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F79883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F79883&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Distal common bile duct stricture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 464px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cholangiogram showing a stricture in the distal common bile duct.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_31_8690=[""].join("\n");
var outline_f8_31_8690=null;
var title_f8_31_8691="Urea and hydrocortisone: Drug information";
var content_f8_31_8691=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Urea and hydrocortisone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?35/16/36099?source=see_link\">",
"    see \"Urea and hydrocortisone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F232505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Carmol-HC&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F232506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ti-U-Lac&reg; H;",
"     </li>",
"     <li>",
"      Uremol&reg; HC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F232511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F232507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Steroid-responsive dermatoses:",
"     </b>",
"     Topical: Apply thin film and rub in well 2-4 times/day. Therapy should be discontinued when control is achieved; if no improvement is seen, reassessment of diagnosis may be necessary.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F232509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F232508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F232498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Carmol-HC&reg;: Urea 10% and hydrocortisone acetate 1% (28 g) [in water soluble vanishing cream base]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F232490\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F11587751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Occlusive dressings may be used during treatment of psoriasis or recalcitrant conditions; discontinue use of occlusive dressings if infection develops.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F232499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inflammation of corticosteroid-responsive dermatoses",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F11587749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to urea, hydrocortisone, or any components of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F11587750\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Adrenal suppression: Systemic absorption of topical corticosteroids may cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Immunosuppression: Prolonged use may result in fungal or bacterial superinfection; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sensitization: Topical use has been associated with local sensitization (redness, irritation); discontinue if sensitization is noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Children may absorb proportionally larger amounts of corticosteroids after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Sulfite: May contain sodium metabisulfate; use caution in patients with sulfite allergy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F232510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F232495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F232496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13293369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have been observed in animals administered potent topical corticosteroids. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13293371\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F13293370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if topical application will result in detectable quantities in breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F232502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Carmol-HC External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-10% (85 g): $232.58",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F232503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Calmurid (ZA);",
"     </li>",
"     <li>",
"      Ti-U-Lac H (CA);",
"     </li>",
"     <li>",
"      Uremol HC (CA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F232501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10106 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.172.26-0E2FFF80EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_31_8691=[""].join("\n");
var outline_f8_31_8691=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232505\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232506\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232511\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232507\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232509\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232508\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232498\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232490\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11587751\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232499\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11587749\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11587750\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232510\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232495\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232496\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13293369\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13293371\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13293370\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232502\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232503\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F232501\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10106\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10106|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?35/16/36099?source=related_link\">",
"      Urea and hydrocortisone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_31_8692="Loperamide: Pediatric drug information";
var content_f8_31_8692=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Loperamide: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"    see \"Loperamide: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/33/41492?source=see_link\">",
"    see \"Loperamide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F189683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-Diarrheal [OTC];",
"     </li>",
"     <li>",
"      Diamode [OTC];",
"     </li>",
"     <li>",
"      Imodium&reg; A-D EZ Chews [OTC];",
"     </li>",
"     <li>",
"      Imodium&reg; A-D for children [OTC];",
"     </li>",
"     <li>",
"      Imodium&reg; A-D [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F189684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Loperamide&reg;;",
"     </li>",
"     <li>",
"      Diarr-Eze;",
"     </li>",
"     <li>",
"      Dom-Loperamide;",
"     </li>",
"     <li>",
"      Imodium&reg;;",
"     </li>",
"     <li>",
"      Loperacap;",
"     </li>",
"     <li>",
"      Novo-Loperamide;",
"     </li>",
"     <li>",
"      PMS-Loperamine;",
"     </li>",
"     <li>",
"      Rhoxal-loperamide;",
"     </li>",
"     <li>",
"      Rho&reg;-Loperamine;",
"     </li>",
"     <li>",
"      Riva-Loperamide;",
"     </li>",
"     <li>",
"      Sandoz-Loperamide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1059857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidiarrheal",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1059852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=see_link\">",
"      see \"Loperamide: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Acute diarrhea:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Initial doses (in first 24 hours):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     2-5 years (13-20 kg): 1 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     6-8 years (21-30): 2 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     9-12 years (&gt;30 kg): 2 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     After initial dosing, 0.1 mg/kg doses after each loose stool but not exceeding initial dosage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;12 years and Adults: 4 mg initially, followed by 2 mg after each loose stool, up to 16 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Chronic diarrhea:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 0.08-0.24 mg/kg/day divided 2-3 times/day, maximum: 2 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 4 mg initially followed by 2 mg after each unformed stool until diarrhea is controlled; reduce dosage to meet individual requirements. When optimal dosage is determined, may administer total dosage once daily or in divided doses. Average daily maintenance dosage: 4-8 mg; if improvement is not seen with 16 mg/day for at least 10 days, symptoms are unlikely to be controlled by further therapy",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F189665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral, as hydrochloride: 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anti-Diarrheal: 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diamode: 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imodium&reg; A-D: 2 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 2 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as hydrochloride: 1 mg/5 mL (120 mL [DSC]); 1 mg/7.5 mL (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imodium&reg; A-D: 1 mg/7.5 mL (240 mL) [creamy-mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imodium&reg; A-D: 1 mg/7.5 mL (120 mL) [contains sodium 10 mg/30 mL, sodium benzoate; creamy-mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imodium&reg; A-D for children: 1 mg/7.5 mL (120 mL) [contains sodium 16 mg/30 mL, sodium benzoate; creamy-mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride: 1 mg/5 mL (5 mL, 10 mL, 118 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anti-Diarrheal: 1 mg/5 mL (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Imodium&reg; A-D EZ Chews: 2 mg [mint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F189652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes chewable tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1059861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Drink plenty of fluids to help prevent dehydration",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1059860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute diarrhea and chronic diarrhea associated with inflammatory bowel disease; chronic functional diarrhea (idiopathic), chronic diarrhea caused by bowel resection or organic lesions; to decrease the volume of ileostomy discharge",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F189734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Imodium&reg; A-D may be confused with Indocin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Loperamide may be confused with furosemide, Lomotil&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Indiaral [France] may be confused with Inderal and Inderal LA brand names for propranolol [U.S., Canada, and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lomotil: Brand name for loperamide [Mexico, Philippines], but also the brand name for diphenoxylate [U.S., Canada, and multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lomotil [Mexico, Phillipines] may be confused with Ludiomil brand name for maprotiline [multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F189732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramping, constipation, nausea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Abdominal distention, abdominal pain, allergic reactions, anaphylactic shock, anaphylactoid reactions, angioedema, bullous eruption (rare), drowsiness, dyspepsia, erythema multiforme (rare), fatigue, flatulence, hypersensitivity, paralytic ileus, megacolon, pruritus, rash, Stevens-Johnson syndrome (rare), toxic epidermal necrolysis (rare), toxic megacolon, urinary retention, urticaria, vomiting, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1059865\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to loperamide or any component; abdominal pain in the absence of diarrhea; children &lt;24 months of age; acute ulcerative colitis; patients who must avoid constipation; infectious diarrhea resulting from organisms that penetrate the intestinal mucosa (eg,",
"     <i>",
"      Shigella",
"     </i>",
"     ,",
"     <i>",
"      Salmonella",
"     </i>",
"     ); patients with pseudomembranous colitis; bloody diarrhea",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1059851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     If clinical improvement in acute diarrhea is not observed in 48 hours, discontinue use; use with caution and monitor patients with hepatic dysfunction closely for CNS toxicity",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1059850\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Discontinue therapy if constipation, abdominal distension, or ileus develop. HIV-positive patients should have therapy discontinued with early signs of abdominal distension due to reports of toxic megacolon in these patients who, while receiving loperamide, developed infectious colitis from both viral and bacterial pathogens.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Imodium&reg; A-D contains benzoic acid and sodium benzoate; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate displaces bilirubin from protein binding sites; avoid use in neonates",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2127373\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F189661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F189662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2127372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal reproduction studies. Information related to loperamide use in pregnancy is limited and data is conflicting (Einarson, 2000; K&auml;ll&eacute;n, 2008). For acute diarrhea in pregnant women, some clinicians recommend oral rehydration and dietary changes; loperamide in small amounts may be used only if symptoms are disabling (Wald, 2003).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1059849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Acts directly on intestinal muscles to inhibit peristalsis and prolong transit time",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1059863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action: Within 30-60 minutes",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1059864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: 40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (&gt;50%) to inactive compounds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 10.8 hours (range 9.1-14.4 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsules: 5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Liquid: 2.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Fecal and urinary (1%) excretion of metabolites and unchanged drug (30% to 40%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1059856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/33/41492?source=see_link\">",
"      see \"Loperamide: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not exceed maximum daily dosage; may cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; if acute diarrhea lasts longer than 48 hours, consult physician; may cause dry mouth; avoid alcohol",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12561 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_31_8692=[""].join("\n");
var outline_f8_31_8692=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189683\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189684\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059857\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059852\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189665\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189652\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059861\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059860\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189734\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189732\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059865\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059851\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059850\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127373\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189661\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189662\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2127372\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059849\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059863\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059864\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1059856\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12561\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12561|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?15/53/16214?source=related_link\">",
"      Loperamide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/33/41492?source=related_link\">",
"      Loperamide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_31_8693="OCT system";
var content_f8_31_8693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F82662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F82662&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Commercially available intracoronary Fourier domain OCT system (Lightlab Imaging Inc, Westford, MA)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) OCT system consisting in (1) console containing the light source, a computer and imaging display screen and (2) the automated pullback device allowing for pullback speeds up to 20 mm/sec.",
"    <br>",
"     (B) OCT imaging catheter (Dragonfly&trade;, Lightlab Imaging Inc, Westford, MA, USA).",
"     <br>",
"      (C) Magnification of the distal OCT catheter tip. The OCT imaging catheter is introduced into the coronary artery using a conventional guide wire in short monorail technique. The short monorail catheter segment is indicated by (1) the radiopaque distal catheter tip marker and (2) a more proximal radiopaque marker; (3) the imaging core is located approx 15 mm proximal to the distal tip marker and moderately radiopaque. During pullback, the imaging core is withdrawn within the transparent catheter sheath, while the OCT imaging catheter itself is stationary within the artery.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Dr. Evelyn Regar, Thoraxcenter.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_31_8693=[""].join("\n");
var outline_f8_31_8693=null;
var title_f8_31_8694="Topiramate: Patient drug information";
var content_f8_31_8694=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Topiramate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     see \"Topiramate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/60/21448?source=see_link\">",
"     see \"Topiramate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F229206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Topamax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F229207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Topiramate&reg;;",
"     </li>",
"     <li>",
"      CO Topiramate;",
"     </li>",
"     <li>",
"      Dom-Topiramate;",
"     </li>",
"     <li>",
"      Mint-Topiramate;",
"     </li>",
"     <li>",
"      Mylan-Topiramate;",
"     </li>",
"     <li>",
"      Novo-Topiramate;",
"     </li>",
"     <li>",
"      PHL-Topiramate;",
"     </li>",
"     <li>",
"      PMS-Topiramate;",
"     </li>",
"     <li>",
"      PRO-Topiramate;",
"     </li>",
"     <li>",
"      ratio-Topiramate;",
"     </li>",
"     <li>",
"      Sandoz-Topiramate;",
"     </li>",
"     <li>",
"      Topamax&reg;;",
"     </li>",
"     <li>",
"      ZYM-Topiramate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028609\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028611\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692054",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat painful nerve diseases.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat headaches.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691473",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop migraine headaches.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to topiramate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696966",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow laws about driving with a seizure problem.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697225",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glaucoma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are on a ketogenic diet, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697284",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney stones, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698393",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Acid balance changes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698605",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Back pain, belly pain, or blood in the urine. May be signs of a kidney stone.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not sweating during activities or in warm temperatures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699064",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698512",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If seizures are worse or not the same after starting this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698670",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, if you get pregnant while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow tablet whole. Do not chew, break, or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696326",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may sprinkle contents of sprinkle capsule on soft food or liquid. Do not chew.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028614\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11108 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-89.32.226.102-73EC6B31EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_31_8694=[""].join("\n");
var outline_f8_31_8694=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229206\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F229207\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028609\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028611\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028610\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028615\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028616\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028618\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028613\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028614\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028619\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028620\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=related_link\">",
"      Topiramate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/60/21448?source=related_link\">",
"      Topiramate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_31_8695="Paraneoplastic pemphigus indirect immunofluorescence esophagus";
var content_f8_31_8695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86500&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Paraneoplastic pemphigus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Indirect immunofluorescence microscopy demonstrates deposition of IgG intercellularly and at the basement membrane zone. The substrate is monkey esophagus. 200X.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_31_8695=[""].join("\n");
var outline_f8_31_8695=null;
var title_f8_31_8696="Spondyloarthropathy in children";
var content_f8_31_8696=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Spondyloarthropathy in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/31/8696/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/31/8696/contributors\">",
"     Thomas JA Lehman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/31/8696/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/31/8696/contributors\">",
"     Marisa Klein-Gitelman, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/31/8696/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/31/8696/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/31/8696/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 25, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spondyloarthropathies in children are a group of pediatric rheumatic diseases characterized by enthesitis and arthritis involving in most cases the lower extremities in the initial years and, in a variable proportion of cases, the sacroiliac and spinal joints some years later [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/1\">",
"     1",
"    </a>",
"    ]. Back involvement is often unsuspected and must be actively sought.",
"   </p>",
"   <p>",
"    The clinical issues associated with childhood spondyloarthropathy, particularly enthesitis-related arthritis (ERA), are discussed here. Detailed discussions of the corresponding disorders in the adult, such as psoriatic arthritis, reactive arthritis, and ankylosing spondylitis, are presented separately. Arthritis associated with inflammatory bowel disease and other gastrointestinal diseases is also discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=see_link\">",
"     \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=see_link\">",
"     \"Clinical manifestations of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=see_link\">",
"     \"Arthritis associated with gastrointestinal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40584?source=see_link\">",
"     \"Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12390?source=see_link\">",
"     \"Psoriatic juvenile idiopathic arthritis: Management and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6058746\">",
"    <span class=\"h1\">",
"     TERMINOLOGY AND CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The terms spondyloarthropathy, spondyloarthropathies, spondyloarthritis, and spondyloarthritides were used to refer to a group of related seronegative (ie, rheumatoid factor negative) inflammatory diseases generally characterized by involvement of the spine (sacroiliitis and spondylitis), large joints (lower limb asymmetric oligoarthritis), and entheses (enthesitis or enthesopathy, inflammation of the sites where tendons or ligaments insert into the bone, especially plantar fascia and the Achilles tendon). Spondyloarthritides are strongly associated with the human leukocyte antigen (HLA) B27, and extraarticular features may be present. Diseases that can fall under this category in children include undifferentiated spondyloarthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, and inflammatory bowel disease associated arthritis.",
"   </p>",
"   <p>",
"    The term enthesitis-related arthritis (ERA) is used in the International League of Associations for Rheumatology (ILAR) classification of juvenile idiopathic arthritis (JIA) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. ERA includes children with arthritis and enthesitis, or arthritis and other features associated with spondyloarthropathy. ERA does not include reactive arthritis and the arthropathy associated with inflammatory bowel disease. Psoriatic arthritis is classified in a different subgroup not related to ERA. Thus, the definition of ERA is only partially similar to that of spondyloarthritis. However, this &lsquo;academic&rsquo; distinction is of no clinical significance, since the therapies for both are identical. In addition, the entire nomenclature is being reworked, which will lead to further changes in definitions.",
"   </p>",
"   <p>",
"    Clinicians should be aware that inflammatory bowel disease, psoriasis, and ankylosing spondylitis may only become obvious years after the original presentation with ERA. Thus, consideration of these entities as distinct from ERA is often erroneous. Furthermore, many children lack axial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extraarticular manifestations on presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/5\">",
"     5",
"    </a>",
"    ]. Over time, these children may develop definite sacroiliitis, leading to a diagnosis of ankylosing spondylitis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=see_link\">",
"     \"Pathogenesis of spondyloarthritis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H5\">",
"     'Laboratory findings'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35717?source=see_link\">",
"     \"Classification of juvenile arthritis (JRA/JIA)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spondyloarthritides rarely present before the second decade of life. They are more common in males than females, and in general start around the age of 8 to 12 years. A family history of similar problems is sometimes present, even in those who are HLA-B27 negative [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=see_link\">",
"     \"Clinical manifestations of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with enthesitis-related arthritis account for 10 to 19 percent of all patients classified with juvenile idiopathic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. However, these children respond differently to medications and have a different natural history and prognosis than children with other forms of juvenile idiopathic arthritis. The relative frequency of spondyloarthropathies among 1742 children with a diagnosed rheumatic condition was 13 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/12\">",
"     12",
"    </a>",
"    ]. However, these data may be biased by the failure of many children with mild spondyloarthropathies to be properly recognized and referred for care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3929247\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The underlying etiology of spondyloarthropathy (including ankylosing spondylitis) is unknown. There is a strong association with HLA-B27 and an infectious etiology has been suggested, but not proven. Various animal models, including an HLA-B27 transgenic rat that may develop psoriasis, axial and peripheral arthritis, and colitis, are helping to shed light on this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/13\">",
"     13",
"    </a>",
"    ]. The pathogenesis of spondyloarthritis, particularly ankylosing spondylitis in adults, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=see_link\">",
"     \"Pathogenesis of spondyloarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with spondyloarthropathies are commonly misdiagnosed initially with recurrent sprains or strains, because the onset of symptoms early in the second decade often coincides with a period of increased physical activity. The disease onset is typically gradual, but in some cases is first recognized following a febrile illness or musculoskeletal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/14\">",
"     14",
"    </a>",
"    ]. The arthritis is usually pauciarticular, asymmetric, and primarily involves the joints of the lower extremities. Enthesitis, when present at the time of diagnosis, also most commonly occurs in the lower extremities [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classic presentation is an adolescent male with knee, ankle, or tarsal swelling. This finding is often initially treated as an injury, but the swelling recurs or fails to respond to orthopedic measures. The detection of painful tendon or ligament insertions (enthesitis) around other joints, or of limited anterior spinal flexion, both suggest that an injury is not responsible. Enthesitis is a prominent feature in approximately 75 percent of cases and is therefore an important diagnostic finding [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/14\">",
"     14",
"    </a>",
"    ]. Around 10 percent of patients may have axial involvement presenting as spinal or sacroiliac joint pain and stiffness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/16\">",
"     16",
"    </a>",
"    ]. Back pain in children with spondyloarthritis has some of the typical features of inflammatory back pain. Morning stiffness is another common finding, and may affect the back and the involved joints. This symptom must be specifically sought as children and their families often do not relate stiffness to the presenting complaint. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although the knee and the ankle are the joints most frequently involved at presentation, recurrent hip pain can also occur. Heel pain is also a frequent manifestation. Many children have been repeatedly misdiagnosed with sprains and strains of these areas. Achilles tendonitis and planta fasciitis are common findings which may be diagnosed as isolated conditions by clinicians failing to recognize that these findings are part of the overall disease.",
"   </p>",
"   <p>",
"    In some children, the swelling of small joints of the hands may be a predominant finding, particularly among girls with psoriatic arthritis. Dactylitis, thought to be due to recurrent \"jamming\" of the finger, is a well-recognized presentation. Over time, these children may progress to significant wrist involvement and limitation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=see_link\">",
"     \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40584?source=see_link\">",
"     \"Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Extraarticular manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of extraarticular manifestations are associated with the spondyloarthropathies. Anterior uveitis, particularly acute anterior inflammation characterized by pain and injection, may occur. Diverse skin manifestations and recurrent gastrointestinal complaints also may occur as part of an undifferentiated spondyloarthropathy. A spondyloarthropathy may also be the initial manifestation of systemic disorders such as inflammatory bowel disease. Delays of several years between the onset of arthritis and evidence of systemic disease are not uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HLA-B27 is present in 90 percent of children with ankylosing spondylitis, but only about 60 percent of children with spondyloarthropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/13,14,17\">",
"     13,14,17",
"    </a>",
"    ]. Although HLA-B27 occurs with an increased frequency in these children, the presence or absence of the allele cannot be relied upon to establish or refute the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=see_link\">",
"     \"Pathogenesis of spondyloarthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Erythrocyte sedimentation rate (ESR) and other laboratory markers of inflammation may be elevated in severe cases, but many children with a spondyloarthropathy have no abnormal laboratory findings. Antinuclear antibodies may be found in the subgroup of psoriatic arthritis not related to spondyloarthritis, but are not routinely present in children with other spondyloarthropathies. Rheumatoid factor is normally absent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35717?source=see_link\">",
"     \"Classification of juvenile arthritis (JRA/JIA)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Radiographic findings often include heel spurs and sacroiliitis in children with ankylosing spondylitis. However, most radiographs are normal early in the course of the disease. Magnetic imaging is significantly more sensitive in detecting early sacroiliitis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, spondyloarthropathies are often initially misdiagnosed with recurrent injuries. Keys to proper recognition include a careful history and a complete physical examination to detect one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oligoarthritis that is usually asymmetric and primarily involves the large joints of the lower extremities.",
"     </li>",
"     <li>",
"      Enthesitis.",
"     </li>",
"     <li>",
"      Inflammatory back pain (insidious onset, mostly worse at night, improves with exercise, does not improve with rest) often accompanied by reduced anterior spinal flexion. In the author&rsquo;s experience, a Schober test is a useful tool in evaluating for lumbosacral spine involvement, particularly in patients who do not yet have radiographic evidence of sacroiliitis. To perform the Schober test, the patient stands erect; the position of the fifth lumbar spinous process is marked by a pen; another mark is made 10 cm above it in the midline. The patient then bends forward maximally without bending the knees. In normal individuals, the distance between the two points should exceed 15 cm (",
"      <a class=\"graphic graphic_figure graphicRef58884 \" href=\"UTD.htm?6/39/6768\">",
"       figure 1",
"      </a>",
"      ). Although children are smaller than adults, they are also more flexible, and 15 cm remains a useful guideline. Measurement of fingertip to floor distance in full flexion may also be used to follow the patient's progress provided that the child does not have flexion contractures of the elbows.",
"     </li>",
"     <li>",
"      Gastrointestinal complaints or other findings suggestive of inflammatory bowel disease; studies in adults with undifferentiated spondyloarthropathy or ankylosing spondylitis suggest that inflammatory bowel disease may be the underlying cause in selected patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6377?source=see_link&amp;anchor=H3#H3\">",
"       \"Mechanisms for the induction of rheumatic symptoms by gastrointestinal disease\", section on 'Arthritis and gastrointestinal disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=see_link\">",
"       \"Arthritis associated with gastrointestinal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sacroiliitis in an adolescent. The interpretation of mild irregularities on standard radiographs is debatable, because the SI joints are still open. Magnetic resonance imaging (MRI) is the preferred method to evaluate for inflammatory sacroiliitis. Demonstration of inflammatory sacroiliitis on MRI strongly supports a diagnosis of a spondyloarthropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Associated diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial assessment also should include evaluation for systemic diseases that may manifest spondyloarthritis. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Inflammatory bowel disease (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=see_link\">",
"       \"Arthritis associated with gastrointestinal disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Psoriatic arthritis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=see_link\">",
"       \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40584?source=see_link\">",
"       \"Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Reactive arthritis (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"       \"Reactive arthritis (formerly Reiter syndrome)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As noted above the musculoskeletal manifestations of these disorders may precede other evidence of the underlying condition by months to years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Inflammatory bowel disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory bowel disease (IBD) may present with typical findings of a spondyloarthropathy with or without the presence of HLA-B27. A variety of findings may be early clues to the presence of inflammatory bowel disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Persistent mild anemia. Anemia is common and is often associated with mild gastrointestinal complaints. Although the anemia may be ascribed to blood loss secondary to a low level of mucosal irritation associated with NSAIDs, it is actually an early manifestation of IBD.",
"     </li>",
"     <li>",
"      Recurrent or persistent aphthous ulcers.",
"     </li>",
"     <li>",
"      Uveitis.",
"     </li>",
"     <li>",
"      Poor growth. Children with IBD may have a preferential deceleration of their longitudinal growth, something not seen in those with isolated arthritis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2794?source=see_link\">",
"       \"Growth failure and poor weight gain in children with inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    All of these findings may be present in patients without underlying IBD; however, any one of them may also be the earliest clue that IBD is the underlying diagnosis. The presence of any of these findings in a child with a family history of IBD is sufficient to suggest referral to a gastroenterologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spondyloarthropathy in general should be differentiated from musculoskeletal injuries or developmental abnormalities such as spondylolisthesis (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical presentation'",
"    </a>",
"    above). Back pain and stiffness are otherwise rare in young children and uncommon in adolescents and should be regarded with great suspicion. Thus, careful evaluation to eliminate orthopedic, neoplastic, and infectious etiologies is important.",
"   </p>",
"   <p>",
"    Enthesitis-related arthritis and psoriatic arthritis are discrete from other forms of juvenile idiopathic arthritis in the ILAR classification, since each of these disorders has a different natural history and prognosis. This distinction, however, is problematic in a significant percentage of patients, one of the major shortcomings of this nomenclature system. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35717?source=see_link\">",
"     \"Classification of juvenile arthritis (JRA/JIA)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with enthesitis-related arthritis (ERA) may ultimately fulfill classification criteria for ankylosing spondylitis (AS) if axial symptoms and radiologic evidence of sacroiliitis are present. A variable proportion of patients with ERA progress to ankylosing spondylitis years after initial presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/5,17\">",
"     5,17",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=see_link\">",
"     \"Clinical manifestations of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H6058746\">",
"     'Terminology and classification'",
"    </a>",
"    above). Thus all patients with ERA should be followed carefully and those with HLA-B27 must be followed with a high index of suspicion that they will evolve into AS.",
"   </p>",
"   <p>",
"    According to the ILAR criteria, definite juvenile psoriatic arthritis is considered to be present if a patient has arthritis with psoriasis, or arthritis with three of four minor criteria (nail pits, dactylitis, psoriasis-like rash, family history of psoriasis); arthritis with two of the minor criteria represents probable psoriatic arthritis that is classified as undifferentiated arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, axial involvement is less common in juvenile psoriatic arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/17\">",
"     17",
"    </a>",
"    ]. Once again, however, up to one-third of children with psoriatic arthritis do not develop a rash until sometime after the arthritis has been present, rendering the diagnosis an ongoing process. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=see_link\">",
"     \"Clinical manifestations and diagnosis of psoriatic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40584?source=see_link\">",
"     \"Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike juvenile idiopathic arthritis, the spondyloarthropathies commonly affect the hips and the back early in the disease course and an enthesitis may be present (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=see_link\">",
"     \"Pauciarticular onset juvenile idiopathic arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=see_link\">",
"     \"Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Mechanical, developmental, and orthopedic disorders other than spondyloarthropathy may affect the hips of children. These include slipped capital femoral epiphysis, Legg-Calve-Perthes disease, and osteoid osteomas. Clinicians can typically distinguish these conditions from spondyloarthropathy based upon the age of the patient and a complete history and physical examination. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=see_link\">",
"     \"Slipped capital femoral epiphysis (SCFE)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of benign bone tumors in children and adolescents\", section on 'Osteoid osteoma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of hip pain in childhood\", section on 'Specific causes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     COURSE AND PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enthesitis-related arthritis is a heterogeneous condition whose course depends in part upon the presence or absence of the allele HLA-B27 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/13\">",
"     13",
"    </a>",
"    ]. Other risk factors for development of sacroiliitis include higher numbers of active joints and entheses at disease onset, hip arthritis, and elevated erythrocyte sedimentation rate (ESR) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/22-24\">",
"     22-24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective series of 59 children with enthesitis-related arthritis, 30 percent developed symptoms of inflammatory back pain with sacroiliitis detectable on dynamic magnetic resonance imaging (MRI), but not radiographs, of sacroiliac joints [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/22\">",
"     22",
"    </a>",
"    ]. The number of active joints and entheses at disease onset were higher in the children who developed sacroiliitis. In a retrospective series of 143 children with spondyloarthritis, hip arthritis was positively associated, and dactylitis negatively associated, with sacroiliitis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/23\">",
"     23",
"    </a>",
"    ]. This study highlights the importance of following patients over a long period of time as many patients with sacroiliitis will develop ankylosing spondylitis within ten years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Absence of HLA-B27",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the absence of HLA-B27, many adolescents have recurrent mild symptoms that may not require medication or are well controlled with the intermittent use of nonsteroidal antiinflammatory drugs (NSAIDs). Significant progression is rare in this group in the absence of an elevated ESR. In comparison, children with an elevated ESR or other evidence of systemic inflammation may have more persistent symptoms; some develop progressive limitation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Presence of HLA-B27",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with HLA-B27 and inflammatory back pain or sacroiliac joint involvement (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Diagnosis'",
"    </a>",
"    above) are at increased risk for the development of ankylosing spondylitis with sacroiliitis. In one report, for example, 10 of 58 patients had evidence of sacroiliitis after an average of five years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/14\">",
"     14",
"    </a>",
"    ]. Many of these children initially have a good response to NSAID therapy; however, a subgroup progresses to significant disability over a period of many years. Children with persistent inflammatory peripheral or axial symptoms or sacroiliitis should be treated with anti-tumor necrosis factor (anti-TNF) agents, since NSAID therapy will not prevent disease progression. Those who develop or present with an associated condition, such as inflammatory bowel disease or psoriasis, have a prognosis that depends upon the severity of that condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of spondyloarthropathy in adolescents does not differ from the treatment rendered to adults with the same conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=see_link\">",
"     \"Assessment and treatment of ankylosing spondylitis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17782?source=see_link\">",
"     \"General guidelines for use of anti-tumor necrosis factor alpha agents in ankylosing spondylitis and axial spondyloarthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=see_link\">",
"     \"Arthritis associated with gastrointestinal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=see_link\">",
"     \"Reactive arthritis (formerly Reiter syndrome)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40234?source=see_link\">",
"     \"Treatment of psoriatic arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The therapeutic approach includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The undifferentiated spondyloarthropathies often respond well to nonsteroidal antiinflammatory drugs (NSAIDs);",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      analogues, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/29/38352?source=see_link\">",
"       diclofenac",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/25/9625?source=see_link\">",
"       piroxicam",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33512?source=see_link\">",
"       tolmetin",
"      </a>",
"      , are frequently effective.",
"     </li>",
"     <li>",
"      Those with systemic manifestations, such as fatigue or anemia, who do not respond to typical NSAIDs within three to six months may improve with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with HLA-B27 negative spondyloarthropathies rarely require treatment with immunosuppressive agents. However, aggressive therapy with anti-TNF agents is recommended for children who have peripheral arthritis or enthesitis unresponsive to treatment or who develop sacroiliitis.",
"     </li>",
"     <li>",
"      Children who have persistent peripheral synovitis may respond to a DMARD, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/27\">",
"       27",
"      </a>",
"      ]. However, axial involvement is usually resistant to these agents [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. Both peripheral synovitis and axial arthritis respond to anti-TNF agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/30-34\">",
"       30-34",
"      </a>",
"      ], although these agents may be less effective in inducing inactive disease in patients with ERA compared with other forms of JIA [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8696/abstract/35\">",
"       35",
"      </a>",
"      ]. Anti-TNF agents may also prevent disease progression. Thus, anti-TNF agents are preferred in children with persistent peripheral synovitis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      axial arthritis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For those children who have or develop associated conditions such as inflammatory bowel disease, the use of glucocorticoids or other disease-specific agents is often necessary to control the extraintestinal manifestations. In many such children, control of the underlying condition is associated with remission of the articular symptoms, but this is not uniformly true.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11837775\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The spondyloarthropathies are a diverse group of arthritides, which typically begin in adolescence and are linked by a predilection for involvement of the back and the large joints of the lower extremities. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The terms spondyloarthropathy, spondyloarthropathies, spondyloarthritis, and spondyloarthritides are used to refer to a group of related seronegative (ie, rheumatoid factor negative) inflammatory diseases with involvement of the spine (sacroiliitis and spondylitis), large joints (asymmetric oligoarthritis, especially of the lower extremities), and entheses (enthesitis or enthesopathy, inflammation of the sites where tendons or ligaments insert into the bone). Diseases that can fall under this category in children include undifferentiated spondyloarthritis, enthesitis-related arthritis, ankylosing spondylitis, psoriatic arthritis, reactive arthritis, and inflammatory bowel disease associated arthritis. (See",
"      <a class=\"local\" href=\"#H6058746\">",
"       'Terminology and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enthesis-related arthritis (ERA) includes children with arthritis and enthesis or arthritis and other features associated with spondyloarthropathy. It excludes the reactive arthropathies, psoriatic arthritis, and the arthropathy associated with inflammatory bowel disease. (See",
"      <a class=\"local\" href=\"#H6058746\">",
"       'Terminology and classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The onset of the disease is often gradual, but may be first recognized following a febrile illness or musculoskeletal trauma. The arthritis is usually pauciarticular, asymmetric, and primarily involves the large joints of the lower extremities. The knee, ankle, and mid-foot are the joints most frequently involved at presentation, and recurrent heel pain can also occur. Common associated features include painful tendon or ligament insertions (enthesitis), inflammatory back or sacroiliac joint pain, morning stiffness, and limited spinal mobility, Achilles tendonitis, plantar fasciitis, swelling of small joints of the hands, and dactylitis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extraarticular findings include anterior uveitis, diverse skin manifestations, and recurrent gastrointestinal complaints. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Extraarticular manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HLA-B27 occurs in most children with ankylosing spondylitis, and is increased in frequency in all of the spondyloarthropathies. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Laboratory findings'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Course and prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic diseases associated with spondyloarthropathy include inflammatory bowel disease, Whipple's disease, psoriatic arthritis, and reactive arthritis. However, the musculoskeletal manifestations of these disorders may precede other evidence of the underlying condition by months to years. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Associated diseases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Enthesitis-related arthritis should be differentiated from the other spondyloarthritides, since each of these disorders has a different natural history and prognosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of spondyloarthropathy in adolescents does not differ materially from the treatment rendered to adults with the same conditions. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/1\">",
"      Burgos-Vargas R. The juvenile-onset spondyloarthritides. Rheum Dis Clin North Am 2002; 28:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/2\">",
"      Fink CW. Proposal for the development of classification criteria for idiopathic arthritides of childhood. J Rheumatol 1995; 22:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/3\">",
"      Petty RE, Southwood TR, Baum J, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritis: Durban, 1997. J Rheumatol 1998; 25:1991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/4\">",
"      Colbert RA. Classification of juvenile spondyloarthritis: Enthesitis-related arthritis and beyond. Nat Rev Rheumatol 2010; 6:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/5\">",
"      Cabral DA, Oen KG, Petty RE. SEA syndrome revisited: a longterm followup of children with a syndrome of seronegative enthesopathy and arthropathy. J Rheumatol 1992; 19:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/6\">",
"      Burgos-Vargas R, Clark P. Axial involvement in the seronegative enthesopathy and arthropathy syndrome and its progression to ankylosing spondylitis. J Rheumatol 1989; 16:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/7\">",
"      Rosenberg AM. Analysis of a pediatric rheumatology clinic population. J Rheumatol 1990; 17:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/8\">",
"      Demirkaya E, Ozen S, Bilginer Y, et al. The distribution of juvenile idiopathic arthritis in the eastern Mediterranean: results from the registry of the Turkish Paediatric Rheumatology Association. Clin Exp Rheumatol 2011; 29:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/9\">",
"      Solau-Gervais E, Robin C, Gambert C, et al. Prevalence and distribution of juvenile idiopathic arthritis in a region of Western France. Joint Bone Spine 2010; 77:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/10\">",
"      Yilmaz M, Kendirli SG, Altintas DU, et al. Juvenile idiopathic arthritis profile in Turkish children. Pediatr Int 2008; 50:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/11\">",
"      Saurenmann RK, Rose JB, Tyrrell P, et al. Epidemiology of juvenile idiopathic arthritis in a multiethnic cohort: ethnicity as a risk factor. Arthritis Rheum 2007; 56:1974.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/12\">",
"      Denardo BA, Tucker LB, Miller LC, et al. Demography of a regional pediatric rheumatology patient population. Affiliated Children's Arthritis Centers of New England. J Rheumatol 1994; 21:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/13\">",
"      Taurog JD. The role of HLA-B27 in spondyloarthritis. J Rheumatol 2010; 37:2606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/14\">",
"      Jacobs JC, Berdon WE, Johnston AD. HLA-B27-associated spondyloarthritis and enthesopathy in childhood: clinical, pathologic, and radiographic observations in 58 patients. J Pediatr 1982; 100:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/15\">",
"      Weiss PF, Klink AJ, Behrens EM, et al. Enthesitis in an inception cohort of enthesitis-related arthritis. Arthritis Care Res (Hoboken) 2011; 63:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/16\">",
"      Burgos-Vargas R, V&aacute;zquez-Mellado J. The early clinical recognition of juvenile-onset ankylosing spondylitis and its differentiation from juvenile rheumatoid arthritis. Arthritis Rheum 1995; 38:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/17\">",
"      Cabral DA, Malleson PN, Petty RE. Spondyloarthropathies of childhood. Pediatr Clin North Am 1995; 42:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/18\">",
"      Bollow M, Braun J, Biedermann T, et al. Use of contrast-enhanced MR imaging to detect sacroiliitis in children. Skeletal Radiol 1998; 27:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/19\">",
"      Pagnini I, Savelli S, Matucci-Cerinic M, et al. Early predictors of juvenile sacroiliitis in enthesitis-related arthritis. J Rheumatol 2010; 37:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/20\">",
"      Weber U, Maksymowych WP. Sensitivity and specificity of magnetic resonance imaging for axial spondyloarthritis. Am J Med Sci 2011; 341:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/21\">",
"      Roberton DM, Cabral DA, Malleson PN, Petty RE. Juvenile psoriatic arthritis: followup and evaluation of diagnostic criteria. J Rheumatol 1996; 23:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/22\">",
"      Pagnini I, Savelli S, Matucci-Cerinic M, et al. Early predictors of juvenile sacroiliitis in enthesitis-related arthritis. J Rheumatol 2010; 37:2395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/23\">",
"      Stoll ML, Bhore R, Dempsey-Robertson M, Punaro M. Spondyloarthritis in a pediatric population: risk factors for sacroiliitis. J Rheumatol 2010; 37:2402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/24\">",
"      Flat&oslash; B, Hoffmann-Vold AM, Reiff A, et al. Long-term outcome and prognostic factors in enthesitis-related arthritis: a case-control study. Arthritis Rheum 2006; 54:3573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/25\">",
"      Gensler L, Davis JC Jr. Recognition and treatment of juvenile-onset spondyloarthritis. Curr Opin Rheumatol 2006; 18:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/26\">",
"      Huang JL, Chen LC. Sulphasalazine in the treatment of children with chronic arthritis. Clin Rheumatol 1998; 17:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/27\">",
"      van der Horst-Bruinsma IE, Clegg DO, Dijkmans BA. Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs. Clin Exp Rheumatol 2002; 20:S67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/28\">",
"      Roychowdhury B, Bintley-Bagot S, Bulgen DY, et al. Is methotrexate effective in ankylosing spondylitis? Rheumatology (Oxford) 2002; 41:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/29\">",
"      Haibel H, Sieper J. Use of methotrexate in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010; 28:S128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/30\">",
"      Henrickson M, Reiff A. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. J Rheumatol 2004; 31:2055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/31\">",
"      Tse SM, Burgos-Vargas R, Laxer RM. Anti-tumor necrosis factor alpha blockade in the treatment of juvenile spondylarthropathy. Arthritis Rheum 2005; 52:2103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/32\">",
"      Sieper J, Rudwaleit M, Braun J. Adalimumab for the treatment of ankylosing spondylitis. Expert Opin Pharmacother 2007; 8:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/33\">",
"      Sulpice M, Deslandre CJ, Quartier P. Efficacy and safety of TNFalpha antagonist therapy in patients with juvenile spondyloarthropathies. Joint Bone Spine 2009; 76:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/34\">",
"      Otten MH, Prince FH, Twilt M, et al. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010. J Rheumatol 2011; 38:2258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8696/abstract/35\">",
"      Donnithorne KJ, Cron RQ, Beukelman T. Attainment of inactive disease status following initiation of TNF-&alpha; inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease. J Rheumatol 2011; 38:2675.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6421 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-41.78.124.10-D70169F40B-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_31_8696=[""].join("\n");
var outline_f8_31_8696=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11837775\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6058746\">",
"      TERMINOLOGY AND CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3929247\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Extraarticular manifestations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Associated diseases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      COURSE AND PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Absence of HLA-B27",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Presence of HLA-B27",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11837775\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6421\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6421|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/39/6768\" title=\"figure 1\">",
"      Low back flexion test",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25289?source=related_link\">",
"      Arthritis associated with gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/23/35194?source=related_link\">",
"      Assessment and treatment of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35717?source=related_link\">",
"      Classification of juvenile arthritis (JRA/JIA)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30488?source=related_link\">",
"      Clinical manifestations and diagnosis of psoriatic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/9/151?source=related_link\">",
"      Clinical manifestations of ankylosing spondylitis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9114?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of undifferentiated spondyloarthritis and related spondyloarthritides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/23/17782?source=related_link\">",
"      General guidelines for use of anti-tumor necrosis factor alpha agents in ankylosing spondylitis and axial spondyloarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/46/2794?source=related_link\">",
"      Growth failure and poor weight gain in children with inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6377?source=related_link\">",
"      Mechanisms for the induction of rheumatic symptoms by gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/60/24522?source=related_link\">",
"      Overview of benign bone tumors in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16729?source=related_link\">",
"      Overview of hip pain in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/51/12090?source=related_link\">",
"      Pathogenesis of spondyloarthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/31/24056?source=related_link\">",
"      Pauciarticular onset juvenile idiopathic arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/25/24983?source=related_link\">",
"      Polyarticular onset juvenile idiopathic arthritis: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/6/12390?source=related_link\">",
"      Psoriatic juvenile idiopathic arthritis: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/40/40584?source=related_link\">",
"      Psoriatic juvenile idiopathic arthritis: Pathogenesis, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/27/33210?source=related_link\">",
"      Reactive arthritis (formerly Reiter syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/42/23209?source=related_link\">",
"      Slipped capital femoral epiphysis (SCFE)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/18/40234?source=related_link\">",
"      Treatment of psoriatic arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_31_8697="Disseminated intravascular coagulation in infants and children";
var content_f8_31_8697=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Disseminated intravascular coagulation in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/31/8697/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/31/8697/contributors\">",
"     Wendy Wong, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/31/8697/contributors\">",
"     Bertil Glader, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/31/8697/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/31/8697/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/31/8697/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/31/8697/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/31/8697/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated intravascular coagulation (DIC) is an acquired syndrome characterized by hemorrhage and microvascular thrombosis. Endothelial tissue damage from a variety of underlying disorders (eg, sepsis, trauma, and malignancy) activates the coagulation cascade, which promotes fibrin production and deposition, and consumption of clotting factors. The subsequent consumption of coagulation factors and platelets, enhanced fibrinolysis, and fibrin deposition result in the clinical picture of DIC of a bleeding diathesis accompanied by thrombosis that may lead to end organ damage (",
"    <a class=\"graphic graphic_algorithm graphicRef78959 \" href=\"UTD.htm?32/4/32846\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef79998 \" href=\"UTD.htm?23/62/24558\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The etiology, clinical manifestations, diagnosis, and treatment of DIC in infants and children will be reviewed here. DIC in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a summary of the pathogenesis of DIC. A more complete discussion is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathogenesis and etiology of disseminated intravascular coagulation\", section on 'Pathogenesis of DIC'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    DIC is a secondary process caused by the systemic activation of the coagulation system by tissue damage from a variety of underlying diseases (eg, sepsis, trauma, and malignancies) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/1\">",
"     1",
"    </a>",
"    ]. The activation of the intravascular coagulation system initiates the following processes (",
"    <a class=\"graphic graphic_algorithm graphicRef78959 \" href=\"UTD.htm?32/4/32846\">",
"     algorithm 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exposure of blood to procoagulants &mdash; Tissue damage from the initiating primary disease releases procoagulants into the bloodstream.",
"     </li>",
"     <li>",
"      Formation of fibrin in the circulation &mdash; Tissue procoagulants activate hemostasis primarily through the interaction of tissue factor and Factor VII, which promotes fibrin formation and deposition within the microcirculation.",
"     </li>",
"     <li>",
"      Fibrinolysis &mdash; Fibrin formation activates the fibrinolysis pathway, which produces plasmin that cleaves fibrinogen and fibrin, thereby generating fibrin degradation products (FDPs). FDPs interfere with fibrin polymerization and impair platelet aggregation.",
"     </li>",
"     <li>",
"      Depletion of clotting factors and platelets &mdash; Ongoing activation of the coagulation system and fibrin deposition consume clotting factors and platelets.",
"     </li>",
"     <li>",
"      End-organ damage &mdash; Deposition of fibrin into the microcirculation of organs results in tissue ischemia and damage.",
"     </li>",
"     <li>",
"      Hemolysis &mdash; Intravascular fibrin strands cause mechanical shearing of red blood cells resulting in microangiopathic hemolytic anemia (",
"      <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;DIC occurs in a variety of clinical conditions (",
"    <a class=\"graphic graphic_table graphicRef59455 \" href=\"UTD.htm?15/6/15468\">",
"     table 1",
"    </a>",
"    ). In older infants and children, the major causes of DIC include sepsis, trauma, and malignancies. In the neonate, DIC is caused primarily by sepsis and perinatal complications (eg, birth asphyxia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Older infants and children",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion is a summary of the causes of DIC in older infants and children, which are similar to those seen in adults. The pathogenesis of each of these etiologies is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=see_link&amp;anchor=H7#H7\">",
"     \"Pathogenesis and etiology of disseminated intravascular coagulation\", section on 'Etiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis is the most common cause of DIC in older infants and children. DIC was classically recognized as a complication of endothelial damage produced by meningococcemia. Viral, rickettsial, fungal, parasitic, and other bacterial infections are also associated with DIC (",
"    <a class=\"graphic graphic_table graphicRef59455 \" href=\"UTD.htm?15/6/15468\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations of meningococcal infection\", section on 'Disseminated intravascular coagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Trauma and tissue injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, DIC potentially is a serious complication of any major trauma or tissue injury. These include crush injury, massive burns, extensive surgery, severe hypothermia, heat exhaustion, and shock. In all these cases, release of tissue enzymes and phospholipids from damaged tissue into the systemic circulation triggers activation of the coagulation system. Brain tissue is a potent thromboplastin and patients who sustain severe brain injury are especially at risk for DIC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with leukemia, laboratory abnormalities in the clotting system are common [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. DIC is rare in children with acute lymphocytic leukemia, although it has been reported in patients with the uncommon t(17;19) translocation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/4\">",
"     4",
"    </a>",
"    ]. Patients with acute promyelocytic leukemia can present with acute hemorrhage due to DIC. In these patients, granules within the blast cells contain procoagulants that directly trigger the coagulation system [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=see_link\">",
"     \"Overview of the complications of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with malignancies are often leukopenic and may develop DIC secondary to sepsis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Miscellaneous",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of DIC in children include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute hemolytic transfusion reactions &mdash; Release of adenosine diphosphate and phospholipids from the hemolyzed red cell activate platelet and the coagulation system respectively.",
"     </li>",
"     <li>",
"      Kasabach Merritt (KM) syndrome &mdash; Patients with kaposiform hemangioendothelioma, an aggressive form of giant hemangioma, can develop KM syndrome, a localized form of DIC. The large hemangioma consumes fibrinogen and platelets resulting in thrombocytopenia and consumptive coagulopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link&amp;anchor=H14#H14\">",
"       \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Kasabach Merritt syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Snake and spider bites &mdash; The venom of some snakes and spiders (eg, rattlesnakes and Russell's viper) can directly activate the coagulation system and lead to DIC.",
"     </li>",
"     <li>",
"      Liver disease &mdash; DIC may be seen in patients with acute or chronic hepatocellular disease including Reye's syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Newborn infants, particularly preterm infants, are vulnerable to DIC because the anticoagulants, antithrombin, and protein C are normally low at this age [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. The main causes of DIC include sepsis, birth asphyxia, respiratory distress syndrome (RDS), and necrotizing enterocolitis (NEC) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal viral infections (eg, rubella, herpes, cytomegalovirus, and enterovirus), systemic candidiasis, and bacterial sepsis (eg, Group B streptococcus and gram-negative organisms) are causes of neonatal DIC. Perinatal acquired infections (eg, TORCH infections) are also associated with DIC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Perinatal conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perinatal conditions associated with DIC include complications from pregnancy and delivery that lead to birth asphyxia, and diseases linked to prematurity [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstetric complications &mdash; Obstetric complications resulting in fetal",
"      <span class=\"nowrap\">",
"       anoxia/birth",
"      </span>",
"      asphyxia may cause neonatal DIC. These include abruptio placentae, preeclampsia, eclampsia, and fetal distress during labor.",
"     </li>",
"     <li>",
"      Conditions associated with prematurity &mdash; DIC is associated with necrotizing enterocolitis (NEC) and respiratory distress syndrome (RDS), both of which are seen more frequently in premature infants. In patients with NEC, ischemic bowel tissue releases tissue factor, which activates the coagulation system. Patients with severe RDS are also at risk for DIC presumably due to tissue damage from hypoxia. Autopsy studies in preterm infants with RDS have demonstrated fibrin deposition not only in the lungs but also the liver and kidney [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/13\">",
"       13",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41591?source=see_link\">",
"       \"Clinical features and diagnosis of necrotizing enterocolitis in newborns\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Miscellaneous &mdash; Rare causes of neonatal DIC include hypothermia and massive hemolysis, such as seen in Rh incompatibility.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Congenital disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital homozygous deficiency of protein C and S can present in the neonatal period with DIC and purpura fulminans, while neonates who have large hemangiomas can develop Kasabach Merritt syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=see_link&amp;anchor=H10#H10\">",
"     \"Protein C deficiency\", section on 'Neonatal purpura fulminans'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=see_link&amp;anchor=H14#H14\">",
"     \"Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism\", section on 'Kasabach Merritt syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the clinical spectrum and causes of DIC are variable in infants and children, the pathophysiology is the same, with an overwhelmed hemostatic system that is unable to compensate for the ongoing consumption of clotting factors and platelets. In these patients, clinical bleeding and microthrombosis occur, and coagulation tests are often abnormal.",
"   </p>",
"   <p>",
"    Clinical findings vary depending on the severity of DIC. In mild cases, bleeding may only be noted at venipuncture sites, but in other cases there may be severe hemorrhage and thrombosis with end-organ damage to the kidney, liver, lung, central nervous system (CNS), and extremities. Hemorrhage is the most common presentation followed by skin manifestations of purpura and acral gangrene (purpura fulminans).",
"   </p>",
"   <p>",
"    In neonates, the most common sites of bleeding are the gastrointestinal tract and venipuncture sites [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/14\">",
"     14",
"    </a>",
"    ]. In severe cases, intrapulmonary and intraventricular hemorrhages occur. Risk factors for DIC in neonates include prematurity, low birth weight, and low Apgar scores (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?13/24/13697?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LABORATORY FINDINGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory findings in DIC are classified based upon the pathologic process:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Consumption of coagulation factors and platelets",
"     </li>",
"     <li>",
"      Increased fibrin formation",
"     </li>",
"     <li>",
"      Increased fibrinolysis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Consumption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tests that show consumption of clotting factors and platelets include the following (",
"    <a class=\"graphic graphic_figure graphicRef79998 \" href=\"UTD.htm?23/62/24558\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Platelet count &mdash; Thrombocytopenia (platelet count &lt;100,000 per mm3) usually is present in patients with DIC. On the peripheral smear, platelets are large, suggesting a destructive process (",
"      <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Prothrombin time (PT) &mdash; The PT is prolonged in 50 to 75 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/15\">",
"       15",
"      </a>",
"      ]. A prolonged PT reflects a reduction in the activity of the extrinsic and common coagulation pathways.",
"     </li>",
"     <li>",
"      Activated partial thromboplastin time (aPTT) &mdash; The aPTT is prolonged in 50 to 60 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/15\">",
"       15",
"      </a>",
"      ]. A prolonged aPTT reflects a reduction in the activity of the intrinsic and common coagulation pathways.",
"     </li>",
"     <li>",
"      Factor V and VIII levels &mdash; Both Factor V (common coagulation pathway) and factor VIII (intrinsic pathway) are decreased (",
"      <a class=\"graphic graphic_figure graphicRef79998 \" href=\"UTD.htm?23/62/24558\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients with DIC will have a normal PT and aPTT as noted above. This may be due to circulating activated clotting factors such as thrombin and factor Xa [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Fibrin formation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies indicative of fibrin formation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibrinogen &mdash; When the fibrinogen concentration is low, it is consistent with a diagnosis of DIC due to its consumption in the formation of fibrin. However, fibrinogen is not a sensitive test for DIC because it is also an acute phase reactant. When the concentration is normal, it may represent a significant decrease in a patient whose fibrinogen level should be higher because of the inflammation from",
"      <span class=\"nowrap\">",
"       his/her",
"      </span>",
"      underlying disease.",
"     </li>",
"     <li>",
"      Thrombin time &mdash; Thrombin time is prolonged when the fibrinogen concentration is low. FDPs also impair fibrin formation, thereby prolonging the thrombin time.",
"     </li>",
"     <li>",
"      Microangiopathic hemolytic anemia &mdash; Microangiopathic changes on the peripheral smear are suggestive of DIC and are due to mechanical shearing of red blood cells by intravascular fibrin strands (",
"      <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"       picture 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Fibrinolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;DIC is unlikely if there is no evidence of fibrinolysis as indicated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fibrin degradation products (FDPs) &mdash; FDPs are products of plasmin degradation of fibrinogen and fibrin [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/15\">",
"       15",
"      </a>",
"      ]. They are present in 85 to 100 percent of patients with DIC. However FDPs are not a specific test, since they are also present in patients who have systemic lupus erythematous, necrotizing enterocolitis, thrombotic events from causes other than DIC, and in some individuals taking oral contraceptives.",
"     </li>",
"     <li>",
"      D-dimer &mdash; D-dimer is a neoantigen produced when cross-linked fibrin is degraded by plasmin. It is elevated in 90 percent of patients with DIC and is more specific than FDPs [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;DIC is also characterized by decreased levels of antithrombin, and protein C and S, which lead to impairment of the anticoagulant pathway. Despite the decreased concentration of these anticoagulants, their measurement generally is not helpful in clinical management.",
"   </p>",
"   <p>",
"    There are several other tests for DIC that may prove to be helpful but are not widely available or used.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Procoagulant activation &mdash; Commercial assays are available to measure markers of procoagulant activation such as prothrombin fragment 1.2, fibrinopeptide A and fibrinopeptide B, and thrombin-antithrombin (TAT) complexes.",
"     </li>",
"     <li>",
"      Fibrinolysis &mdash; Fibrinolysis can be detected by elevated levels of plasmin and plasmin-antiplasmin (PAP) complex.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;In neonates, establishing normal values for clotting factors and coagulation tests have been hampered by:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Changes in concentration of coagulation factors and coagulation test values with gestational and postnatal age.",
"     </li>",
"     <li>",
"      Difficulties in obtaining adequate control groups of healthy preterm and term infants.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Normal ranges for coagulation tests and concentrations of specific clotting factors have been reported for full-term infants and preterm infants (&gt;30 weeks gestation) from birth to six months postnatal age (",
"    <a class=\"graphic graphic_table graphicRef52172 \" href=\"UTD.htm?8/44/8910\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef65080 \" href=\"UTD.htm?9/62/10223\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. These values are based upon studies that included 72 fullterm infants [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/9\">",
"     9",
"    </a>",
"    ], 70 preterm infants born at 34 to 36 weeks gestational age (GA), and 67 infants born at 30 to 33 weeks GA [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/10\">",
"     10",
"    </a>",
"    ]. In extremely preterm infants (GA &lt;27 weeks), factor V and VIII are higher than vitamin K-dependent clotting factors. The level of vitamin K-dependent factors also increases with increasing gestational age [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When interpreting coagulation tests, it is imperative to recognize the differences in the normal values of coagulation tests between the neonatal and adult patient [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/7\">",
"     7",
"    </a>",
"    ]. As an example, aPTT is normally prolonged in fullterm infants at birth compared to adults (mean values, 42.9 &plusmn; 11.6 versus 33.5 &plusmn; 6.8 sec, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/9\">",
"     9",
"    </a>",
"    ]. This difference is even greater in the preterm infant (mean value for infants 30 to 36 weeks gestation, 53.6 &plusmn; 26.1) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/10\">",
"     10",
"    </a>",
"    ]. The aPTT in both preterm and term infants decreases to adult values by six months of age.",
"   </p>",
"   <p>",
"    Physiologic levels of factors V, VIII, and fibrinogen in fullterm infants are similar to those in adults and can serve as diagnostic markers for DIC in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/7\">",
"     7",
"    </a>",
"    ]. In preterm infants, fibrinogen concentration is low and D-dimer is commonly present without DIC, limiting their value in the diagnosis of DIC. In addition, neonates have relatively decreased amounts of plasma due to their higher hematocrit levels and therefore it is imperative that the correct anticoagulant to plasma ratio is obtained in the blood specimens to ensure accurate testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of overt DIC is based upon clinical findings of hemorrhage and microthrombi in patients with predisposing medical conditions and abnormal coagulation studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although laboratory studies are used to support the diagnosis, there is no single test that is sensitive or specific enough to assure a definite diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/17\">",
"     17",
"    </a>",
"    ]. A reasonable panel of coagulation studies to establish the diagnosis includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count (CBC)",
"     </li>",
"     <li>",
"      Prothrombin time (PT)",
"     </li>",
"     <li>",
"      Activated partial thromboplastin time (aPTT)",
"     </li>",
"     <li>",
"      D-dimer level",
"     </li>",
"     <li>",
"      Fibrinogen level",
"     </li>",
"     <li>",
"      Factor V and VIII levels",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Adding to the challenge of establishing the diagnosis, every patient with DIC does not have positive findings consistent with DIC in all laboratory studies. The most helpful tests clinically are those that indicate the presence of fibrinolysis (eg, FDPs and D-dimers). D-dimer is a more specific test for DIC than FDPs. The latex agglutination assay for D-dimer is commonly used and is one of the more reliable tests. In addition, decreased levels of factors V and VIII help substantiate the diagnosis of DIC.",
"   </p>",
"   <p>",
"    Serial measurements of coagulation parameters are more informative than laboratory measurements performed at a single timepoint. As an example, a prothrombin time, which is in the upper normal range but is significantly longer than an earlier measurement, reflects the consumptive process of DIC and not a normal hemostatic state. Serial measurements of platelet counts that document a downward trend are a sensitive but not specific sign for DIC [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Scoring system",
"    </span>",
"    &nbsp;&mdash;&nbsp;A scoring system to simplify the diagnosis of DIC has been developed by the DIC subcommittee of the International Society on Thrombosis and Haemostasis (ISTH) (",
"    <a class=\"graphic graphic_algorithm graphicRef74304 \" href=\"UTD.htm?35/59/36798\">",
"     algorithm 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/19\">",
"     19",
"    </a>",
"    ]. This scoring system is based upon:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients having a medical condition known to be associated with DIC.",
"     </li>",
"     <li>",
"      Readily available global coagulation tests that include platelet count, FDPs, PT, and fibrinogen concentration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Scores are dependent on the degree of abnormality measured by each test. As an example, a platelet count",
"    <span class=\"nowrap\">",
"     &lt;50,000/microL",
"    </span>",
"    is scored higher than one that is",
"    <span class=\"nowrap\">",
"     &lt;100,000/microL.",
"    </span>",
"   </p>",
"   <p>",
"    A preliminary study in critically ill adults with DIC reported a 91 percent sensitivity and 97 percent specificity for the ISTH scoring system compared to clinical expert opinion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/20\">",
"     20",
"    </a>",
"    ]. A review of the literature demonstrated several studies that have reported accurate prediction of mortality with the use of this scoring system [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/21\">",
"     21",
"    </a>",
"    ]. The system score also correlated with other markers of DIC including decreased antithrombin and protein C activity, and increased TAT complexes and soluble fibrin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/20\">",
"     20",
"    </a>",
"    ]. The DIC subcommittee of the ISTH is developing a similar template for children and infants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to older patients, the diagnosis of DIC in the neonate relies on abnormal global coagulation tests in the appropriate clinical setting [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/22\">",
"     22",
"    </a>",
"    ]. However, it is more difficult to establish the diagnosis of DIC in these patients. Testing is limited because the volume of blood required may be difficult to attain in the neonate. In addition, the interpretation of these studies in the neonate is challenging as the hemostatic system is still in a state of flux at birth with physiologic alterations of coagulation and fibrinolysis. As a result, the diagnosis of DIC in the neonate may rely more heavily on the patient's clinical manifestations than on laboratory studies. The recognition of the underlying condition rather than establishing the diagnosis of DIC is more important as the most important therapeutic intervention is to treat the underlying disorder. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Laboratory evaluation'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H29\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical differential diagnosis for DIC is broad and includes those diseases that present with bleeding. The laboratory evaluation, however, usually differentiates DIC from these other diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link\">",
"     \"Approach to the child with bleeding symptoms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Thrombocytopenia and normal coagulation tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, the main cause of destructive thrombocytopenia is immune thrombocytopenia (ITP, previously known as idiopathic thrombocytopenic purpura). It is differentiated from DIC as patients with ITP have normal coagulation tests. In contrast to patients with DIC who appear sickly, the vast majority of patients with ITP are well appearing besides findings of petechiae and ecchymoses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemolytic uremic syndrome (HUS), like DIC, presents with thrombocytopenia and microangiopathic hemolytic anemia. Although in most patients with HUS, PT and aPTT are normal, severe cases may have abnormal coagulation tests. In these patients, the history and clinical setting are important to differentiate between the two conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Neonate",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the neonate, causes of consumptive thrombocytopenia without evidence of other coagulation abnormalities include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alloimmune neonatal thrombocytopenia",
"     </li>",
"     <li>",
"      Maternal idiopathic thrombocytopenia",
"     </li>",
"     <li>",
"      Renal vein thrombosis",
"     </li>",
"     <li>",
"      Bacterial and viral infections",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=see_link\">",
"     \"Neonatal thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Abnormal coagulation tests and normal platelet count",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many conditions that present with bleeding and have abnormal PT and aPTT but a normal platelet count. These include genetic disorders of specific clotting factor deficiency (eg, Hemophilia due to factors VIII and IX deficiency), and are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=see_link&amp;anchor=H28#H28\">",
"     \"Approach to the child with bleeding symptoms\", section on 'Normal platelet count'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hepatic failure and vitamin K deficiency have similar clinical findings as those with DIC but have normal platelet counts. Bleeding from the latter is often seen in neonates who do not receive prophylactic vitamin K at birth.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Normal coagulation tests and platelet count",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with disorders of platelet function (eg, Glanzmann thrombasthenia), factor XIII deficiency, and fibrinolytic pathway defects (eg, plasminogen activator inhibitor, PAI-1, deficiency) can present with bleeding diathesis but their screening coagulation tests and platelet counts will be normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;DIC is a serious complication of the underlying primary disease. As a result, successful treatment of DIC is dependent on identifying and treating the underlying cause, thereby removing the triggering factors implicated in the DIC process. In some cases, successful treatment of the underlying cause will lead to resolution of DIC. In others, despite vigorous therapy directed towards the primary disease, coagulation abnormalities persist resulting in significant hemorrhage",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombosis with organ damage. These patients have a high rate of mortality, and as a result, commonly receive DIC supportive therapy.",
"   </p>",
"   <p>",
"    There is no consensus on how supportive therapy should be used due to the paucity of data. In general, supportive care is divided into component replacement and anticoagulation therapy. Treatment is individualized based upon a patient's age, severity of clinical symptoms, underlying primary disorder, and overall clinical status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Replacement therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no randomized controlled trials to study the efficacy of platelet, fresh frozen plasma (FFP), or cryoprecipitate transfusions in children or adults with DIC. Nevertheless, the use of these agents seems rational in patients with significant bleeding due to thrombocytopenia and clotting factor consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Our approach for replacement therapy in patients with DIC is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Replacement therapy should not be routinely given to correct coagulation tests or in children with mild clinical signs of bleeding (eg, a few petechiae or positive guaiac test) [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Replacement therapy is indicated in patients with significant bleeding symptoms (eg, melena or prolonged bleeding from venipuncture sites) or who are at high risk for bleeding because of an impending invasive procedure.",
"     </li>",
"     <li>",
"      The goal of replacement therapy is to reduce or stop significant bleeding. Although replacement therapy should not be used to normalize laboratory tests (which often is impossible), a reasonable guide for the judicious use of blood components in the setting of significant bleeding includes maintaining platelet counts &gt;50,000 per mm3 and fibrinogen concentration &gt;100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1",
"      <span class=\"nowrap\">",
"       mol/L)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clotting factors can be replaced by either FFP or cryoprecipitate. FFP provides both procoagulant and anticoagulant proteins and is administered every 12 to 24 hours at a dose of 10 to 15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per infusion. Cryoprecipitate has higher concentrations of factor VIII and fibrinogen, and can be used to correct hypofibrinogenemia. It is administered every 6 hours as needed at a dose of 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per infusion. Platelet transfusions are administered with a goal of maintaining the platelet counts &gt;50,000 per mm3.",
"   </p>",
"   <p>",
"    Repeat transfusions may be necessary. The theoretical concern of replacement therapy increasing thrombotic risk by \"adding fuel to the fire\" has not been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/15\">",
"     15",
"    </a>",
"    ], and should not dissuade the clinician from administering replacement therapy to control significant bleeding. Clinicians should monitor for volume overload in patients who receive factor replacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation therapy can be divided into administration of extrinsic anticoagulants (ie,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    ) or restoration of endogenous anticoagulant proteins (ie, antithrombin).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the administration of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    to interrupt the underlying coagulopathy would appear to be a logical therapeutic approach, there are no controlled trials that demonstrate a benefit in children or adults with DIC. A major concern regarding the use of heparin is its potential to aggravate bleeding. It is contraindicated in patients with CNS injury or liver failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link&amp;anchor=H28#H28\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     Heparin",
"    </a>",
"    had been routinely used in patients with clinically overt thrombosis and potential end-organ failure. However, there is little evidence that its use improved organ dysfunction. However, new guidelines suggest that for patients who are critically ill from DIC but without bleeding, prophylactic doses of heparin or low molecular weight heparin (LMWH) are recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/22\">",
"     22",
"    </a>",
"    ]. In most cases of DIC, heparin infusion is not indicated. It is our practice to administer heparin only to patients with life-threatening or symptomatic thrombi (eg, Acral ischemia or skin infection) without clinical bleeding.",
"   </p>",
"   <p>",
"    Once the decision is made to administer",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"     heparin",
"    </a>",
"    , continuous infusion of unfractionated heparin is probably the best choice given the risk of bleeding. The dose of unfractionated heparin is 5 to 10",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    per hour by constant intravenous infusions. LMWH has been used in adults but there are no data to assess its effectiveness in children. Another note of caution in using LMWH in children is the need to monitor Anti-Xa levels due to increased metabolism of the medication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link&amp;anchor=H28#H28\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Anticoagulant restoration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The levels of both antithrombin and protein C are decreased in DIC. It is reasonable to think that administration of these anticoagulants may have a beneficial effect in management as restoration of these proteins may reduce microthrombus formation. In addition to fresh frozen plasma, which provides anticoagulant and procoagulant factors, there are specific protein C and antithrombin concentrates.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Human",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/27/39349?source=see_link\">",
"       protein C concentrate",
"      </a>",
"      &mdash; Protein C concentrate is not biologically active on administration; it is converted to the activated form in vivo. Its clinical utility is limited to very specific disorders: &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Congenital protein C deficiency &ndash; Human",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/27/39349?source=see_link\">",
"       protein C concentrate",
"      </a>",
"      is effective for prophylaxis and treatment of venous thrombosis and purpura fulminans in patients with severe congenital protein C deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=see_link&amp;anchor=H21#H21\">",
"       \"Management of thrombosis in the newborn\", section on 'Neonatal purpura fulminans'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Severe sepsis and purpura fulminans &ndash; Limited evidence suggests that human",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/27/39349?source=see_link\">",
"       protein C concentrate",
"      </a>",
"      may be effective in selected patients with severe sepsis and purpura fulminans. In a randomized, placebo-controlled, dose-finding study in 40 children with severe meningococcal sepsis with purpura fulminans, administration of protein C concentrate yielded increased plasma levels of activated protein C, improvement of coagulation defects, and no adverse reaction.&nbsp;However, this study was underpowered to detect survival outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/25\">",
"       25",
"      </a>",
"      ]. A European retrospective study of 94 pediatric patients with sepsis (mainly meningococcemia) reported that patients given protein C concentrate had clinical improvement of DIC, with lower amputation and skin graft rates, and without an increased risk of bleeding compared to historic controls [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/26\">",
"       26",
"      </a>",
"      ].&nbsp;These preliminary data are encouraging and supportive for a potential role of protein C concentrates in severe DIC with sepsis. However, more data on safety and efficacy of protein C concentrates are needed before it can be recommended for treatment of DIC. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13354?source=see_link&amp;anchor=H1584851#H1584851\">",
"       \"Septic shock: Ongoing management after resuscitation in children\", section on 'Treat disseminated intravascular coagulation'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Activated",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/27/39349?source=see_link\">",
"       protein C concentrate",
"      </a>",
"      &ndash; Recombinant activated protein C (aPC, drotrecogin alfa) is not recommended for treatment of DIC or other coagulation disorders, and is no longer available. Although beneficial effects of this drug were initially reported in patients with sepsis, further randomized studies in adults and children failed to show benefit [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/27\">",
"       27",
"      </a>",
"      ]. Furthermore, there appears to be a risk for bleeding complications in infants younger than two months of age, as suggested by a systematic review of five randomized trials [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/28\">",
"       28",
"      </a>",
"      ]. Drotrecogin alfa was voluntarily removed from the world market in 2011. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29960?source=see_link&amp;anchor=H2552815#H2552815\">",
"       \"Investigational and ineffective therapies for sepsis\", section on 'Ineffective therapies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antithrombin &mdash; In children, there are minimal data on the use of antithrombin [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/29\">",
"       29",
"      </a>",
"      ]. In adults, data suggest that antithrombin proved no benefit in patients with severe sepsis or shock. Antithrombin should not be used until further studies demonstrate that it is effective and safe. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=see_link&amp;anchor=H31#H31\">",
"       \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\", section on 'Antithrombin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Investigational therapy &mdash; Recombinant human soluble thrombomodulin (Recomodulin: Asahi Kasei Pharma, Tokyo, Japan), a new agent which inactivates coagulation by binding to thrombin and activates protein C, is being investigated in patients with DIC. A phase III clinical trial in Japanese patients greater than 15 years of age with DIC from infection or malignancy, showed promising results in comparison to",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/39/7801?source=see_link\">",
"       heparin",
"      </a>",
"      therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8697/abstract/30,31\">",
"       30,31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/62/994?source=see_link\">",
"       \"Patient information: Disseminated intravascular coagulation (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disseminated intravascular coagulation (DIC) is an acquired syndrome due to activation of the coagulation system by a variety of underlying disorders (eg, sepsis, trauma, and malignancy), (",
"    <a class=\"graphic graphic_table graphicRef59455 \" href=\"UTD.htm?15/6/15468\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Pathogenesis'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3\">",
"     'Etiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical manifestations vary depending on the ability of the hemostatic system to compensate for the ongoing depletion of coagulation factors and platelets. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of DIC is based upon clinical findings of hemorrhage and microthrombi in patients with predisposing underlying conditions, and abnormal coagulation tests. No single test, but rather a variety of coagulation studies, are used to confirm the diagnosis. It is imperative to recognize that neonatal values of laboratory tests used to establish the diagnosis of DIC are different from adult values (",
"      <a class=\"graphic graphic_table graphicRef52172 \" href=\"UTD.htm?8/44/8910\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef65080 \" href=\"UTD.htm?9/62/10223\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical differential diagnosis for DIC is broad and includes those diseases that present with bleeding. The laboratory evaluation usually differentiates DIC from other causes of bleeding in children. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of the underlying primary disease is of central importance in controlling DIC. In patients with significant bleeding, we recommend the administration of replacement therapy with platelets and coagulation factors (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/1\">",
"      Levi M. Disseminated intravascular coagulation. Crit Care Med 2007; 35:2191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/2\">",
"      Abshire TC, Gold SH, Odom LF, et al. The coagulopathy of childhood leukemia. Thrombin activation or primary fibrinolysis? Cancer 1990; 66:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/3\">",
"      Ribeiro RC, Pui CH. The clinical and biological correlates of coagulopathy in children with acute leukemia. J Clin Oncol 1986; 4:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/4\">",
"      Hunger SP. Chromosomal translocations involving the E2A gene in acute lymphoblastic leukemia: clinical features and molecular pathogenesis. Blood 1996; 87:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/5\">",
"      Barbui T, Falanga A. Disseminated intravascular coagulation in acute leukemia. Semin Thromb Hemost 2001; 27:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/6\">",
"      Pegelow C, Goldberg R, Turkel S, Powars D. Severe coagulation abnormalities in Reye syndrome. J Pediatr 1977; 91:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/7\">",
"      Andrew M. The relevance of developmental hemostasis to hemorrhagic disorders of newborns. Semin Perinatol 1997; 21:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/8\">",
"      Kreuz W, Veldmann A, Fischer D, et al. Neonatal sepsis: a challenge in hemostaseology. Semin Thromb Hemost 1999; 25:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/9\">",
"      Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the full-term infant. Blood 1987; 70:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/10\">",
"      Andrew M, Paes B, Milner R, et al. Development of the human coagulation system in the healthy premature infant. Blood 1988; 72:1651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/11\">",
"      Veldman A, Fischer D, Nold MF, Wong FY. Disseminated intravascular coagulation in term and preterm neonates. Semin Thromb Hemost 2010; 36:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/12\">",
"      Woods WG, Luban NL, Hilgartner MW, Miller DR. Disseminated intravascular coagulation in the newborn. Am J Dis Child 1979; 133:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/13\">",
"      GAJL-PECZALSKA K. PLASMA PROTEIN COMPOSITION OF HYALINE MEMBRANE IN THE NEWBORN AS STUDIES BY IMMUNOFLUORESCENCE. Arch Dis Child 1964; 39:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/14\">",
"      Buchanan GR. Coagulation disorders in the neonate. Pediatr Clin North Am 1986; 33:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/15\">",
"      Bick RL. Disseminated intravascular coagulation current concepts of etiology, pathophysiology, diagnosis, and treatment. Hematol Oncol Clin North Am 2003; 17:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/16\">",
"      Poralla C, Traut C, Hertfelder HJ, et al. The coagulation system of extremely preterm infants: influence of perinatal risk factors on coagulation. J Perinatol 2012; 32:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/17\">",
"      Favaloro EJ. Laboratory testing in disseminated intravascular coagulation. Semin Thromb Hemost 2010; 36:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/18\">",
"      Akca S, Haji-Michael P, de Mendon&ccedil;a A, et al. Time course of platelet counts in critically ill patients. Crit Care Med 2002; 30:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/19\">",
"      Taylor FB Jr, Toh CH, Hoots WK, et al. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/20\">",
"      Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med 2004; 32:2416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/21\">",
"      Toh CH, Hoots WK, SSC on Disseminated Intravascular Coagulation of the ISTH. The scoring system of the Scientific and Standardisation Committee on Disseminated Intravascular Coagulation of the International Society on Thrombosis and Haemostasis: a 5-year overview. J Thromb Haemost 2007; 5:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/22\">",
"      Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 2009; 145:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/23\">",
"      Williams MD, Chalmers EA, Gibson BE, Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. The investigation and management of neonatal haemostasis and thrombosis. Br J Haematol 2002; 119:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/24\">",
"      Franchini M, Manzato F. Update on the treatment of disseminated intravascular coagulation. Hematology 2004; 9:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/25\">",
"      de Kleijn ED, de Groot R, Hack CE, et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double-blinded, placebo-controlled, dose-finding study. Crit Care Med 2003; 31:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/26\">",
"      Veldman A, Fischer D, Wong FY, et al. Human protein C concentrate in the treatment of purpura fulminans: a retrospective analysis of safety and outcome in 94 pediatric patients. Crit Care 2010; 14:R156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/27\">",
"      Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007; 369:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/28\">",
"      Mart&iacute;-Carvajal AJ, Sol&agrave; I, Lathyris D, Cardona AF. Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2011; :CD004388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/29\">",
"      Hanada T, Abe T, Takita H. Antithrombin III concentrates for treatment of disseminated intravascular coagulation in children. Am J Pediatr Hematol Oncol 1985; 7:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/30\">",
"      Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost 2007; 5:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8697/abstract/31\">",
"      Ogawa E, Yagasaki H, Kato M, et al. Successful treatment of disseminated intravascular coagulation in a child with acute myelogenous leukaemia using recombinant thrombomodulin. Br J Haematol 2010; 149:911.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5915 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_31_8697=[""].join("\n");
var outline_f8_31_8697=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H34\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Older infants and children",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Sepsis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Trauma and tissue injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Miscellaneous",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Neonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Sepsis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Perinatal conditions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Congenital disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LABORATORY FINDINGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Consumption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Fibrin formation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Fibrinolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Other studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Scoring system",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Neonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Thrombocytopenia and normal coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Neonate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Abnormal coagulation tests and normal platelet count",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Normal coagulation tests and platelet count",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Replacement therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Anticoagulant restoration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5915\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5915|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?32/4/32846\" title=\"algorithm 1\">",
"      Pathophysiology of DIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?35/59/36798\" title=\"algorithm 2\">",
"      Diagnostic algorithm for the diagnosis of overt DIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5915|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/62/24558\" title=\"figure 1\">",
"      Coagulation pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5915|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/50/38694\" title=\"picture 1\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5915|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/6/15468\" title=\"table 1\">",
"      Causes DIC children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/44/8910\" title=\"table 2\">",
"      Coagulation test Fullterm NB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/62/10223\" title=\"table 3\">",
"      Coagulation test Preterm NB",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?13/24/13697?source=related_link\" title=\"calculator 1\">",
"      Calculator: Apgar score",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3722?source=related_link\">",
"      Approach to the child with bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/39/41591?source=related_link\">",
"      Clinical features and diagnosis of necrotizing enterocolitis in newborns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/55/35704?source=related_link\">",
"      Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/17/23833?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/52/37704?source=related_link\">",
"      Clinical manifestations of meningococcal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/62/9194?source=related_link\">",
"      Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/16/29960?source=related_link\">",
"      Investigational and ineffective therapies for sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/40/14986?source=related_link\">",
"      Management of thrombosis in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/9/14490?source=related_link\">",
"      Neonatal thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/53/14168?source=related_link\">",
"      Overview of the complications of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/56/8073?source=related_link\">",
"      Pathogenesis and etiology of disseminated intravascular coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/62/994?source=related_link\">",
"      Patient information: Disseminated intravascular coagulation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/52/841?source=related_link\">",
"      Protein C deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13354?source=related_link\">",
"      Septic shock: Ongoing management after resuscitation in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_31_8698="Medical treatment of benign prostatic hyperplasia";
var content_f8_31_8698=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical treatment of benign prostatic hyperplasia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/31/8698/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/31/8698/contributors\">",
"     Glenn R Cunningham, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/31/8698/contributors\">",
"     Dov Kadmon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/31/8698/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/31/8698/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/31/8698/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/31/8698/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/31/8698/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benign prostatic hyperplasia (BPH) becomes increasingly common as men age (",
"    <a class=\"graphic graphic_figure graphicRef55614 \" href=\"UTD.htm?27/51/28477\">",
"     figure 1",
"    </a>",
"    ). BPH can lead to urinary symptoms that may benefit from medical or surgical treatment. However, many men with BPH are asymptomatic or have only mild symptoms and may not require therapy.",
"   </p>",
"   <p>",
"    The medical therapy of BPH will be reviewed here. Surgical and other invasive therapies, the clinical manifestations, natural history, diagnosis of BPH, and the epidemiology and pathogenesis of BPH are all discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=see_link\">",
"     \"Surgical and other invasive therapies of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=see_link\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/19/34104?source=see_link\">",
"     \"Epidemiology and pathogenesis of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lower urinary tract symptoms (LUTS) in men of uncertain etiology, or from etiologies other than BPH, also are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11290?source=see_link\">",
"     \"Lower urinary tract symptoms in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of different terms and abbreviations are used when discussing symptomatic BPH. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lower urinary tract symptoms (LUTS)",
"     </li>",
"     <li>",
"      Benign prostatic enlargement (BPE)",
"     </li>",
"     <li>",
"      Benign prostatic obstruction (BPO)",
"     </li>",
"     <li>",
"      Bladder outlet obstruction (BOO)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    BPE is the physical enlargement of the prostate that occurs as the result of the histologic changes of BPH. BPO is BOO in the setting of BPE.",
"   </p>",
"   <p>",
"    BPE and BOO secondary to BPH are frequently diagnosed clinically on the basis of LUTS. We will use the abbreviation",
"    <span class=\"nowrap\">",
"     BPH/LUTS",
"    </span>",
"    for LUTS presumed to be secondary to BPH, sometimes called symptomatic BPH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The common symptoms of BPH are increased frequency of urination, nocturia, hesitancy, urgency, and weak urinary stream. These symptoms typically appear slowly and progress gradually over a period of years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, these symptoms only require therapy if they have a significant impact on a patient's quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/1\">",
"     1",
"    </a>",
"    ]. Even without therapy, many men will experience stabilization or improvement in symptoms over time [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/2\">",
"     2",
"    </a>",
"    ]. One review found that over a follow-up period of 2.6 to 5 years, 16 percent of men had stable symptoms and 38 percent improved [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/3\">",
"     3",
"    </a>",
"    ]. Thus, the decision to treat",
"    <span class=\"nowrap\">",
"     BPH/LUTS",
"    </span>",
"    involves balancing the severity of the patient's symptoms with potential side effects of therapy.",
"   </p>",
"   <p>",
"    BPH may also require therapy if BOO is creating a risk for upper tract injury such as hydronephrosis or renal insufficiency, or lower tract injury such as urinary retention, recurrent infection, or bladder decompensation (eg, low pressure detrusor contractions; post-void residuals of &gt;25 percent of total bladder volume) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/4\">",
"     4",
"    </a>",
"    ]. In general, patients who develop these symptoms will require invasive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=see_link\">",
"     \"Surgical and other invasive therapies of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to treat is usually based on the severity of symptoms and the patient's tolerance for these symptoms. Use of the AUA symptom score (also known as the International Prostate Symptom Score [IPSS]) (",
"    <a class=\"graphic graphic_table graphicRef57680 \" href=\"UTD.htm?21/50/22317\">",
"     table 1",
"    </a>",
"    ) permits quantitation of symptom severity and monitoring of symptom progression over time. Additionally, the IPSS adds a question about \"bother\" to the AUA score. These questionnaires are easy and quick to complete; however, not all clinicians use them to assess symptoms.",
"   </p>",
"   <p>",
"    Urine flow rate during voiding can also be easily measured. This is a noninvasive test that is readily available to urologists, but usually is not available to primary care clinicians. Thus, medical treatment usually is initiated on the basis of symptoms in the primary care setting.",
"   </p>",
"   <p>",
"    When symptoms occur in the setting of autonomic or severe peripheral neuropathy or following invasive treatment of the urethra or prostate, patients should be referred for urologic evaluation rather than started on treatment by a primary care clinician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bladder outlet obstruction of BPH has two components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A dynamic (physiologic, reversible) component related to the tension of prostatic smooth muscle in the prostate, prostate capsule, and bladder neck",
"     </li>",
"     <li>",
"      A fixed (structural) component related to the bulk of the enlarged prostate impinging upon the urethra",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two classes of drugs, alpha-adrenergic antagonists and 5-alpha-reductase inhibitors, act upon the dynamic and fixed components of bladder outlet obstruction, respectively.",
"   </p>",
"   <p>",
"    Alpha-adrenergic antagonists appear to be more effective than 5-alpha-reductase inhibitors for short-term and long-term treatment of",
"    <span class=\"nowrap\">",
"     BPH/LUTS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/5\">",
"     5",
"    </a>",
"    ]. However, only 5-alpha-reductase inhibitors have demonstrated the potential for long-term reduction in prostate volume and need for prostate surgery. The use of agents from both classes in combination may be superior to using either class alone.",
"   </p>",
"   <p>",
"    Antiandrogens and gonadotropin-releasing hormone (GnRH) agonists also have been used. GnRH agonists may be somewhat more effective for",
"    <span class=\"nowrap\">",
"     BPH/LUTS",
"    </span>",
"    than the above medications, but the resulting androgen deficiency generally makes their use unacceptable to patients.",
"   </p>",
"   <p>",
"    Studies, using surveys and claims data, have examined which therapies are most commonly chosen for patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In the United States, many patients are initially managed with watchful waiting [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/6\">",
"     6",
"    </a>",
"    ]; those who are prescribed a medication are most likely prescribed an alpha-adrenergic antagonist [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. Initial management with watchful waiting appears to be somewhat less common in Europe; initial therapy with an alpha-adrenergic antagonist appears to be most common [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Alpha-1-adrenergic antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five long-acting alpha-1-antagonists,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"     terazosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/55/26485?source=see_link\">",
"     alfuzosin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/15/17653?source=see_link\">",
"     silodosin",
"    </a>",
"    have been approved by the Food and Drug Administration in the United States for treatment of the symptoms of BPH [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/9\">",
"     9",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"     Prazosin",
"    </a>",
"    , a short-acting alpha-1-antagonist, is generally not used for BPH, due to need for frequent dosing and the potential for more cardiovascular side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha-1-adrenergic antagonists such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"     terazosin",
"    </a>",
"    act against the dynamic component of bladder outlet obstruction by relaxing smooth muscle in the bladder neck, prostate capsule, and prostatic urethra.",
"   </p>",
"   <p>",
"    Alpha-1 receptors are abundant in the prostate and base of the bladder, and sparse in the body of the bladder [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. The density of these receptors is increased in hyperplastic prostatic tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Three alpha-1 adrenoreceptor sub-types have been characterized: 1A, 1B, and 1D.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"     Terazosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/55/26485?source=see_link\">",
"     alfuzosin",
"    </a>",
"    antagonize all three receptor subtypes with similar affinity, whereas",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    demonstrates relative selectivity for alpha-1A and -1D receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/13\">",
"     13",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/15/17653?source=see_link\">",
"     Silodosin",
"    </a>",
"    is a relatively selective alpha-1A receptor antagonist [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alpha-1A subtype receptors comprise approximately 70 percent of adrenoreceptors in prostate tissue whereas alpha-1B receptors are more prevalent in smooth muscle of the vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. The alpha-1D subtype receptors comprise less than 30 percent of prostatic adrenoreceptors and are located in prostatic stromal elements [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/16\">",
"     16",
"    </a>",
"    ]. Alpha-1D receptors are also found in the detrusor muscle of the bladder, bladder neck, and the sacral region of the spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one report, there was a direct relationship between the smooth muscle content of prostatic tissue and the increase in maximal urinary flow rate in men with BPH treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"     terazosin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/17\">",
"     17",
"    </a>",
"    ]. In vitro studies showed that terazosin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    , but not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    , caused prostatic apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In a randomized trial of over 500 men with LUTS treated for three months with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/55/26485?source=see_link\">",
"     alfuzosin",
"    </a>",
"    , there was no reduction in prostate volume [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/20\">",
"     20",
"    </a>",
"    ]. Changes in prostate volume have not been shown to correlate with clinical efficacy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approved alpha-1-adrenergic antagonists appear to have similar efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/21,22\">",
"     21,22",
"    </a>",
"    ], although there have been few direct comparisons. A meta-analysis of trials with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/55/26485?source=see_link\">",
"     alfuzosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"     terazosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    published prior to October 1998 provides an overview of the efficacy and side effects of these drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/23\">",
"     23",
"    </a>",
"    ]. There were 6333 men in placebo-controlled trials and 507 men in comparative studies. The results indicated that the drugs were more effective than placebo and that the efficacy of the drugs was similar. In the drug-treated men, the symptom scores (",
"    <a class=\"graphic graphic_table graphicRef57680 \" href=\"UTD.htm?21/50/22317\">",
"     table 1",
"    </a>",
"    ) decreased 30 to 40 percent, and urinary flow rates increased 16 to 25 percent.",
"   </p>",
"   <p>",
"    The selective alpha-1D antagonist, naftopidil, may also be effective although long term randomized controlled trials are needed prior to recommendation for use [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis comparing alpha-adrenergic antagonist monotherapy versus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    (a 5-alpha-reductase inhibitor),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"     terazosin",
"    </a>",
"    were more effective in improving urinary symptoms compared to finasteride [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/5\">",
"     5",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     Tamsulosin",
"    </a>",
"    and finasteride were equally effective.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/55/26485?source=see_link\">",
"     Alfuzosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/15/17653?source=see_link\">",
"     silodosin",
"    </a>",
"    , and naftopidil were not studied in this meta-analysis. (See",
"    <a class=\"local\" href=\"#H10\">",
"     '5-alpha-reductase inhibitors'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiation and dose titration is shown in a table (",
"    <a class=\"graphic graphic_table graphicRef60702 \" href=\"UTD.htm?5/42/5805\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Medication therapy for",
"    <span class=\"nowrap\">",
"     BPH/LUTS",
"    </span>",
"    is generally ongoing. Patients who remain symptomatic on a submaximal dose of an alpha-adrenergic antagonist, and are not experiencing adverse effects, should have the dose increased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Side effects and interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the above meta-analysis, the drugs differed in their side-effect profiles [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/23\">",
"     23",
"    </a>",
"    ]. In clinical trials, the rates of withdrawal for side effects were similar to placebo for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/55/26485?source=see_link\">",
"     alfuzosin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    (4 to 10 percent), while with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"     terazosin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    an additional 4 to 10 percent of men withdrew for side effects.",
"   </p>",
"   <p>",
"    The most important side effects were orthostatic hypotension and dizziness.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"     Terazosin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    generally need to be initiated at bedtime (to reduce postural lightheadedness soon after starting the medication) and the dose should be titrated up over several weeks. If there is a hiatus in drug administration, retitration is usually required.",
"   </p>",
"   <p>",
"    The hypotensive action can be useful in older men who have hypertension, but they require careful monitoring. Alpha-1-adrenergic antagonists may increase the incidence of heart failure when used as monotherapy for hypertension. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link&amp;anchor=H23#H23\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\", section on 'Alpha blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     Tamsulosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/55/26485?source=see_link\">",
"     alfuzosin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/15/17653?source=see_link\">",
"     silodosin",
"    </a>",
"    have lower potential to cause hypotension and syncope than either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"     terazosin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/15,25-27\">",
"     15,25-27",
"    </a>",
"    ], and tamsulosin may further have slightly less effect on blood pressure than alfuzosin [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/23\">",
"     23",
"    </a>",
"    ]. These differential effects on blood pressure by different alpha-1-antagonists may be due to their differential blocking of alpha-1A receptor subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Mechanism'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The hypotensive effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"     terazosin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    can be potentiated by concomitant use of the phosphodiesterase-5 (PDE-5) inhibitors",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    . The risks with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    are less clear. We feel that men who are on lower doses of terazosin or doxazosin and are not experiencing orthostatic blood pressure changes can be treated with PDE-5 inhibitors as long as dosing is separated by at least four hours.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     Tamsulosin",
"    </a>",
"    at a dose of 0.4",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    does not appear to significantly potentiate the hypotensive effects of sildenafil [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other common side effects of alpha-1-antagonists include asthenia and nasal congestion.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     Tamsulosin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/15/17653?source=see_link\">",
"     silodosin",
"    </a>",
"    , in particular, can affect ejaculation. In one study, tamsulosin decreased mean ejaculate volume in more than 90 percent of patients, with 35 percent having no ejaculate; this problem was not observed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/55/26485?source=see_link\">",
"     alfuzosin",
"    </a>",
"    10 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/30\">",
"     30",
"    </a>",
"    ]. Silodosin produces retrograde ejaculation in approximately 28 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     5-alpha-reductase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two 5-alpha-reductase inhibitors approved in the United States,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;These drugs act by reducing the size of the prostate gland. Treatment for 6 to 12 months is generally needed before prostate size is sufficiently reduced to improve symptoms. The type 2 form of 5-alpha-reductase catalyzes the conversion of testosterone to dihydrotestosterone in the prostate, hair follicles, and other androgen-sensitive tissues. Its clinical importance is suggested by the observation that men with inactivating mutations of the gene for the enzyme have very small prostate glands and do not develop BPH [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/31\">",
"     31",
"    </a>",
"    ]. The type 1 form of the enzyme is present in liver, non-genital skin, and some areas of the brain [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a multicenter trial 895 men with BPH were treated with placebo or 1 or 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    for 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/33\">",
"     33",
"    </a>",
"    ]. The following benefits were noted in the men treated with finasteride:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum dihydrotestosterone concentrations decreased by about 70 percent and serum testosterone concentrations increased by 10 percent in both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      treatment groups.",
"     </li>",
"     <li>",
"      A reduction in obstructive and non-obstructive symptom scores by 23 and 18 percent, respectively, in the men given 5 mg daily but less in the men given 1 mg daily and none in the men given placebo.",
"     </li>",
"     <li>",
"      An increase in maximal urinary flow rate of 1.6",
"      <span class=\"nowrap\">",
"       mL/sec",
"      </span>",
"      in the men given 5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      versus 1.4.",
"      <span class=\"nowrap\">",
"       mL/sec",
"      </span>",
"      with 1",
"      <span class=\"nowrap\">",
"       mg/day,",
"      </span>",
"      and 0.2",
"      <span class=\"nowrap\">",
"       mL/sec",
"      </span>",
"      with placebo. The baseline value was approximately 7.3",
"      <span class=\"nowrap\">",
"       mL/sec;",
"      </span>",
"      values above 15",
"      <span class=\"nowrap\">",
"       mL/sec",
"      </span>",
"      are usually associated with no obstructive symptoms.",
"     </li>",
"     <li>",
"      A reduction in mean prostatic volume by 19 and 18 percent in the two treatment groups versus 3 percent in the placebo group.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    appears to persist with long-term treatment. As an example, a trial of over 3000 men who were treated daily with 5 mg of finasteride or placebo demonstrated that the improvements in symptom scores, maximal urinary flow rates, and prostate volume were maintained for more than four years [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/34\">",
"     34",
"    </a>",
"    ]. The most important findings were that finasteride treatment decreased the probability of surgery (5 versus 10 percent, risk reduction 55 percent) and acute urinary retention (3 versus 7 percent, risk reduction 57 percent) (",
"    <a class=\"graphic graphic_figure graphicRef81016 \" href=\"UTD.htm?13/22/13678\">",
"     figure 2",
"    </a>",
"    ). Patients who remained on finasteride for six years in an open-label extension of the study had sustained benefits [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    is greater in men with larger prostate volumes than in men with smaller prostate volumes. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Short-term efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     Finasteride",
"    </a>",
"    increases the apoptotic index of epithelial and stromal cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/36\">",
"     36",
"    </a>",
"    ] and decreases the volume of epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/37\">",
"     37",
"    </a>",
"    ]. After 12 months of treatment finasteride also decreases detrusor pressure at maximum flow rates in men with larger prostate glands (&gt;40 mL) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     Finasteride",
"    </a>",
"    also may suppress gross hematuria in those in whom other causes (particularly prostate and bladder cancer) have been ruled out [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. In a randomized trial, 57 men with BPH, evidence of bleeding from friable prostatic tissue on flexible cystoscopy, and chronic intermittent gross hematuria with no other identifiable cause were assigned to finasteride or a control arm [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/39\">",
"     39",
"    </a>",
"    ]. Finasteride was associated with a lower rate of recurrent hematuria (14 versus 63 percent) and of surgery for bleeding (0 versus 26 percent).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     Dutasteride",
"    </a>",
"    is an inhibitor of both 5-alpha reductase enzymes and may be more potent than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    . In a trial in 4325 men with BPH, dutasteride reduced the risk of acute urinary retention by 57 percent and surgical intervention by 48 percent, and also reduced prostate volume and symptoms after 24-month follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/41\">",
"     41",
"    </a>",
"    ]. A subsequent trial found similar results after 48-month follow-up in men with BPH randomly assigned to dutasteride, compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Enlarged Prostate International Comparator Study (EPICS), an industry-sponsored trial, compared treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    for 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/43\">",
"     43",
"    </a>",
"    ]. The primary outcome reported, reduction in prostate volume, was not significantly different for the two drugs, although this outcome may not have clinical significance. The drugs were also not significantly different in the secondary endpoints of urinary flow rate and urinary symptom scores, and adverse effects were similar.",
"   </p>",
"   <p>",
"    The 5-alpha-reductase inhibitors are more effective in men with larger prostates, and their effects on acute urinary retention and reduction in need for surgery require chronic treatment for more than a year.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike with alpha antagonists, dosing with 5-alpha-reductase inhibitors do not require titration.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     Finasteride",
"    </a>",
"    can be initiated and maintained at 5 mg once daily. Similarly,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    can be initiated and maintained at 0.5 mg once daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major side effects of these drugs are decreased libido and ejaculatory or erectile dysfunction. These occurred in 4 to 6 percent of men in a randomized trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/33\">",
"     33",
"    </a>",
"    ]. Rates of sexual dysfunction in a primary care trial of finasteride were somewhat higher (13.8 percent for any sexual adverse event) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/44\">",
"     44",
"    </a>",
"    ], and this may be more reflective of clinical practice. However, in a long-term trial of finasteride versus placebo in 3040 men with BPH, adverse sexual effects were increased only during the first year of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serum prostate-specific antigen (PSA) concentrations decrease by about 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/33\">",
"     33",
"    </a>",
"    ], a change that must be kept in mind in interpreting the results of serum PSA measurements in men treated with this drug [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/46\">",
"     46",
"    </a>",
"    ]. Findings from the Prostate Cancer Prevention Trial suggest that PSA values be corrected by a factor of 2 for the first 24 months of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    use, and by a factor of 2.5 for longer term use [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=see_link&amp;anchor=H10#H10\">",
"     \"Measurement of prostate specific antigen\", section on 'Benign prostatic hyperplasia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     Finasteride",
"    </a>",
"    does not cause loss of bone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/48\">",
"     48",
"    </a>",
"    ], perhaps because serum estradiol concentrations do not change. A case-control study found no positive association between use of finasteride and hip fracture, and actually found some evidence of lower risk of fracture with finasteride use [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In randomized trials, 5-alpha-reductase inhibitors significantly decrease the incidence of prostate cancer. However, concern has been raised about whether 5-alpha-reductase inhibitors increase the incidence of high-grade lesions, although many believe this finding is spurious. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=see_link&amp;anchor=H6#H6\">",
"     \"Chemoprevention strategies in prostate cancer\", section on '5-Alpha reductase inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The United States Food and Drug Administration (FDA) recommends that before starting 5-alpha reductase inhibitors for treatment of BPH, the patient should be assessed for other urological conditions, including prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/50\">",
"     50",
"    </a>",
"    ]. This advisory from the FDA emphasizes the need to monitor these patients for prostate cancer and to recognize the effect that these drugs have on PSA levels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=see_link\">",
"     \"Clinical presentation and diagnosis of prostate cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=see_link\">",
"     \"Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Discontinuation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have examined what happens when 5-alpha-reductase inhibitor therapy is discontinued after a course of therapy in men with",
"    <span class=\"nowrap\">",
"     BPH/LUTS.",
"    </span>",
"    Most commonly, such therapy is continued indefinitely.",
"   </p>",
"   <p>",
"    One study that examined this issue involved observational follow-up of a randomized trial that compared one year of therapy with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    in men on ongoing alpha blocker therapy; prostate volume and symptoms were monitored after discontinuation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/51\">",
"     51",
"    </a>",
"    ]. At one year after discontinuation, prostate volume had increased 19 to 21 percent, and symptom scores had worsened.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term therapy with combined alpha adrenergic antagonist and 5-alpha-reductase inhibitor therapy appears to be superior to either agent alone in men with",
"    <span class=\"nowrap\">",
"     BPH/LUTS",
"    </span>",
"    and larger prostate glands [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/52\">",
"     52",
"    </a>",
"    ], but not in men with only moderate BPH [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. Long-term combination therapy provides some added benefit even in men with moderate BPH [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Short-term efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the Veterans Affairs Cooperative Study, 1229 men with BPH (mean peak urinary flow rate of 10.5",
"    <span class=\"nowrap\">",
"     mL/sec)",
"    </span>",
"    were randomly assigned to placebo,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"     terazosin",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    or both for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/53\">",
"     53",
"    </a>",
"    ]. Eligibility was based upon an American Urological Association symptom score of at least eight, a maximal urinary flow rate of no more than 15",
"    <span class=\"nowrap\">",
"     mL/sec,",
"    </span>",
"    and a residual urine volume of less than 300 mL; prostate size was not a factor. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"       Terazosin",
"      </a>",
"      lowered the symptom score and increased the peak urinary flow rate when compared with placebo.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       Finasteride",
"      </a>",
"      alone was no better than placebo.",
"     </li>",
"     <li>",
"      The combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"       terazosin",
"      </a>",
"      was no better than terazosin alone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar findings were noted in the PREDICT trial in which 1095 men were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    , or both for one year [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/55\">",
"     55",
"    </a>",
"    ]. Doxazosin was more effective than finasteride or placebo for urinary symptoms and flow rate, but again, the combination was no more effective than doxazosin alone.",
"   </p>",
"   <p>",
"    The mean prostate volume in these studies was approximately 37 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/53,55\">",
"     53,55",
"    </a>",
"    ], lower than the mean volume of approximately 60 mL in the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     Finasteride",
"    </a>",
"    Study Group trial of finasteride alone [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Long-term efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials have found that long-term combination therapy is superior to single-drug therapy for BPH symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of long-term therapy was evaluated in the Medical Therapy of Prostatic Symptoms (MTOPS) trial, in which 3047 men with BPH were randomly assigned to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    , (4 to 8",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    combination therapy, or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/56\">",
"     56",
"    </a>",
"    ]. The mean prostate volume was 36&plusmn;20 mL. The patients were evaluated for symptomatic improvement and overall clinical disease progression, defined as an increase above baseline of at least four points in the AUA symptom score, acute urinary retention, urinary incontinence, renal insufficiency, or recurrent urinary tract infection. Long-term combination therapy lowered the risk of overall clinical progression of BPH significantly more than treatment with either drug alone. In addition, combination therapy or finasteride alone (but not doxazosin alone) reduced the risk of acute urinary retention and the need for invasive therapy.",
"   </p>",
"   <p>",
"    At a mean follow-up of 4.5 years, the following results were seen (",
"    <a class=\"graphic graphic_figure graphicRef74866 \" href=\"UTD.htm?15/32/15872\">",
"     figure 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk of overall clinical progression was reduced to a similar degree by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"       doxazosin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      (39 and 34 percent, respectively, when compared to placebo).",
"     </li>",
"     <li>",
"      Combination therapy reduced the risk of clinical progression by 66 percent, significantly greater than with either drug alone.",
"     </li>",
"     <li>",
"      Symptom scores improved with all therapies, but to a greater degree with combined therapy.",
"     </li>",
"     <li>",
"      Combination therapy or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      alone (but not",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"       doxazosin",
"      </a>",
"      alone) reduced the risk of acute urinary retention and the need for invasive therapy.",
"     </li>",
"     <li>",
"      The number needed to treat to prevent one instance of overall clinical progression was 8.4 for combination therapy, 13.7 for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"       doxazosin",
"      </a>",
"      , and 15.0 for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Adverse effects were similar with combination therapy and monotherapy, with the exception of abnormal ejaculation, peripheral edema, and dyspnea, which were more common with combination therapy. Breast cancer risk was not increased in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      -only or combination therapy groups.",
"     </li>",
"     <li>",
"      A systematic review of the literature concluded that the combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"       doxazosin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      compared with doxazosin alone improves urinary symptoms in men with medium (25 to &lt;40 mL) and large (&gt;40 mL) prostates in the long-term [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The four year CombAT study provides additional evidence that combination therapy is effective in men with larger prostates [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/57\">",
"     57",
"    </a>",
"    ]. CombAT included men with BPH age 50 or older, an IPSS of at least 12, a prostate volume &ge;30 mL, a PSA &ge;1.5 to 10",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    and a maximum urinary flow rate &gt;5mL and",
"    <span class=\"nowrap\">",
"     &le;15/second.",
"    </span>",
"    Subjects were randomly assigned to therapy with",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/dutasteride-drug-information?source=see_link\">",
"     dutasteride",
"    </a>",
"    ,",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/tamsulosin-drug-information?source=see_link\">",
"     tamsulosin",
"    </a>",
"    , or both; there was no double placebo arm. Mean prostate volume in the 4844 men studied was approximately 55 mL.Combination therapy was superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    monotherapy, but not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"     dutasteride",
"    </a>",
"    monotherapy, in reducing the relative risk of acute urinary retention or BPH-related surgery. Combination therapy also was superior to either monotherapy in reducing BPH symptoms and the relative risk of BPH clinical progression (",
"    <a class=\"graphic graphic_figure graphicRef74866 \" href=\"UTD.htm?15/32/15872\">",
"     figure 3",
"    </a>",
"    ). However, more drug-related adverse events were seen with combination therapy than with monotherapy. Dutasteride alone or in combination with tamsulosin reduced the number of prostate biopsies by 40 percent and the relative risk of prostate cancer by 40 percent in men [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Antimuscarinics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some men with",
"    <span class=\"nowrap\">",
"     BPH/LUTS",
"    </span>",
"    may also have frequency, urgency, and incontinence related to an overactive bladder. Bladder contractions are stimulated by acetylcholine effects on muscarinic receptors in smooth muscle of the bladder. A randomized trial in patients with moderate to severe obstructive symptoms, at least a moderate bother score, and urgency found that combination therapy with an anticholinergic agent with antimuscarinic effects (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14646?source=see_link\">",
"     tolterodine",
"    </a>",
"    ) plus an alpha-1-adrenergic antagonist (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    ) was reasonably safe with few episodes of urinary retention [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/59\">",
"     59",
"    </a>",
"    ]. There was some suggestion that combination therapy was more effective than tamsulosin alone. Use of antimuscarinic agents should be restricted to men with low post-void residual volumes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11290?source=see_link\">",
"     \"Lower urinary tract symptoms in men\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Herbal therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herbal therapies for BPH are commonly used in Europe; these remedies comprised 70 percent of spending for drug treatment of prostatism in Germany in 1997 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/60\">",
"     60",
"    </a>",
"    ]. Saw palmetto is approved by the German Commission E for stage I and II (mild to moderate) BPH. Two herbal extracts have officially been approved for the treatment of prostatism in France. No herbal therapies have been approved by the United States Food and Drug Administration for this purpose, although many men probably try these treatments. There is a substantial placebo effect associated with herbal therapy, as there is for most drugs used to treat BPH.",
"   </p>",
"   <p>",
"    The data concerning efficacy of these therapies are conflicting. In systematic reviews of controlled trials, saw palmetto plant extract was as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"     finasteride",
"    </a>",
"    in relieving the symptoms of prostate obstruction, although it did not decrease prostate volume [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/61\">",
"     61",
"    </a>",
"    ]. A subsequent placebo-controlled trial found no evidence that saw palmetto was superior to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/62\">",
"     62",
"    </a>",
"    ]. The evidence regarding the use of saw palmetto for BPH is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33061?source=see_link\">",
"     \"Clinical use of saw palmetto\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is some evidence for efficacy of other agents as well. Systematic reviews have suggested the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The plant extract beta-sitosterol improved symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cernilton, which is prepared from the rye grass pollen, Secale cereale, has been evaluated in four clinical trials [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/64\">",
"       64",
"      </a>",
"      ]. It improved symptoms, but did not affect urinary flow rates or residual urine or prostate volume.",
"     </li>",
"     <li>",
"      Pygeum africanum is an extract of bark from an African plum tree. In a meta-analysis of 18 randomized controlled trials, active treatment improved symptoms two times more frequently than placebo and increased peak urinary flow rates 23 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these systematic reviews, questions regarding safety and efficacy remain. As has been seen with saw palmetto&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33061?source=see_link\">",
"     \"Clinical use of saw palmetto\"",
"    </a>",
"    ), better designed trials do not always confirm the favorable results seen in less well-designed studies. Additionally, questions regarding standardization remain, particularly in the US. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=see_link\">",
"     \"Overview of herbal medicine and dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Until additional studies of herbals are performed, we suggest using alpha-adrenergic antagonists and 5-alpha-reductase inhibitors rather than any of the above herbal therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies suggested that phosphodiesterase-5 (PDE-5) inhibitors, primarily used as treatments for erectile dysfunction, were beneficial for",
"    <span class=\"nowrap\">",
"     BPH/LUTS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/66\">",
"     66",
"    </a>",
"    ] and led to subsequent clinical trials. In a meta-analysis of five randomized trials of men with LUTS secondary to BPH, PDE-5 inhibitors led to significant improvement in IPSS after &ge;12 weeks of therapy, compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/67\">",
"     67",
"    </a>",
"    ]. There was no significant difference in urodynamic parameters. A report found maximum urine flow rates as well as symptom scores to be improved by daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/68\">",
"     68",
"    </a>",
"    ]. The long-term effect of PDE-5 inhibitors in patients with BPH is unclear. Tadalafil is approved by the US Food and Drug Administration for use in BPH. It seems reasonable to discuss this option with men who have erectile dysfunction and mild or moderate symptoms of BPH. Daily dosing of tadalafil should not be prescribed in men with a creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p>",
"    As discussed above, PDE-5 inhibitors can potentiate the hypotensive effects of alpha-1-adrenergic antagonists. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Side effects and interactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is some evidence that nonsteroidal antiinflammatory drugs (NSAIDs) can reduce symptoms of",
"    <span class=\"nowrap\">",
"     BPH/LUTS",
"    </span>",
"    without improving urine flow rates [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     MODIFICATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who experience side effects with either alpha-adrenergic antagonists or 5-alpha-reductase inhibitors can reasonably be switched to the other agent. Patients who have obstructive symptoms on an alpha-adrenergic antagonist may be candidates for antimuscarinic treatment if they have low post-void residual volumes, and patients who do not tolerate any of these therapies can be observed off therapy or can be referred for invasive therapy.",
"   </p>",
"   <p>",
"    Patients who are on combination therapy and do not experience an adequate response over 12 to 24 months may wish to consider invasive therapies as well. Patients with progression of disease on therapy will generally require invasive therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=see_link\">",
"     \"Surgical and other invasive therapies of benign prostatic hyperplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OTHER STRATEGIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with",
"    <span class=\"nowrap\">",
"     BPH/LUTS",
"    </span>",
"    should avoid medications that can exacerbate symptoms or induce urinary retention. These include anticholinergic medications such as sedating antihistamines and adrenergic agents such as decongestants.",
"   </p>",
"   <p>",
"    Behavioral modifications may be helpful. These include avoiding fluids prior to bedtime or before going out, reducing consumption of mild diuretics such as caffeine and alcohol, and double voiding to empty the bladder more completely.",
"   </p>",
"   <p>",
"    A randomized trial found that, compared with men followed with watchful waiting alone, men given an educational intervention that included teaching of behavioral modifications were significantly less likely to experience treatment failure (mainly an increase in IPSS or requirement for medication) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     ECONOMIC CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of",
"    <span class=\"nowrap\">",
"     BPH/LUTS",
"    </span>",
"    is estimated to cost more than $4 billion per year in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/71\">",
"     71",
"    </a>",
"    ]. While the short-term costs of medical treatment are less than those of invasive treatment, many have questioned whether invasive treatment might be less expensive in the long run.",
"   </p>",
"   <p>",
"    One study that examined this question in 970 privately insured men concluded that surgery was associated with higher costs and failure rates over a five year period, and medical therapy remained less expensive than invasive therapy over the long term [",
"    <a class=\"abstract\" href=\"UTD.htm?8/31/8698/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/21/15698?source=see_link\">",
"       \"Patient information: Benign prostatic hyperplasia (enlarged prostate) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/51/28467?source=see_link\">",
"       \"Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Benign prostatic hyperplasia (BPH) becomes increasingly common as men age. BPH can lead to urinary symptoms that may benefit from medical or surgical treatment. However, many men with BPH are asymptomatic or have only mild symptoms and may not require therapy. Additionally, many men with symptoms will improve or stabilize without therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications for therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, men who develop upper tract injury (eg, hydronephrosis, renal dysfunction) or lower tract injury (eg, urinary retention, recurrent infection, bladder decompensation) require invasive therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=see_link\">",
"       \"Surgical and other invasive therapies of benign prostatic hyperplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest that men with symptoms of BPH be instructed in behavior modifications (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). These should be tailored to symptoms but may include avoiding fluids prior to bedtime or before going out, reducing consumption of mild diuretics such as caffeine and alcohol, and double voiding to empty the bladder more completely. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Other strategies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alpha-adrenergic antagonists provide immediate therapeutic benefits, while 5-alpha-reductase inhibitors require long-term treatment for efficacy. In most men with mild to moderate symptoms of BPH where those symptoms have a sufficient effect on quality of life that they desire therapy, we suggest initial treatment with an alpha-adrenergic antagonist alone (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). In men with severe symptoms, those with a large prostate (&gt;40 g), and in those who do not get an adequate response to maximal dose monotherapy with an alpha-adrenergic antagonist, we suggest combination treatment with an alpha-adrenergic antagonist and a 5-alpha-reductase inhibitor (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Combination therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of alpha-adrenergic antagonist and 5-alpha-reductase inhibitor may be made on the basis of cost and side-effect profile.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/28/39365?source=see_link\">",
"       Tamsulosin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?25/55/26485?source=see_link\">",
"       alfuzosin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/15/17653?source=see_link\">",
"       silodosin",
"      </a>",
"      have less effect on blood pressure than either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36085?source=see_link\">",
"       terazosin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/59/8119?source=see_link\">",
"       doxazosin",
"      </a>",
"      , and tamsulosin may further have slightly less effect on blood pressure than alfuzosin. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Alpha-1-adrenergic antagonists'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The two 5-alpha-reductase inhibitors,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39301?source=see_link\">",
"       finasteride",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36372?source=see_link\">",
"       dutasteride",
"      </a>",
"      , appear to have similar efficacy and similar adverse effects. The agents are more effective in men with larger prostates, and their effects on acute urinary retention and reduction in need for invasive therapies require chronic treatment for more than a year. (See",
"      <a class=\"local\" href=\"#H10\">",
"       '5-alpha-reductase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In men with low post-void residual urine volumes and irritative symptoms (eg, frequency, urgency) that persist during treatment with an alpha-adrenergic antagonist, we suggest treatment with an antimuscarinic agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Side effects may be minimized by using a low dose of short-acting medications (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/19/14646?source=see_link\">",
"       tolterodine",
"      </a>",
"      1 mg twice daily). Alternatives include extended-release tolterodine, M3 selective drugs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43733?source=see_link\">",
"       darifenacin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/33/39445?source=see_link\">",
"       solifenacin",
"      </a>",
"      ), or quaternary amines (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/9/26773?source=see_link\">",
"       trospium",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Antimuscarinics'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11290?source=see_link\">",
"       \"Lower urinary tract symptoms in men\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/1\">",
"      McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011; 185:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/2\">",
"      Chapple CR. Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 2004; 94:738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/3\">",
"      Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate Suppl 1990; 3:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/4\">",
"      Burnett AL, Wein AJ. Benign prostatic hyperplasia in primary care: what you need to know. J Urol 2006; 175:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/5\">",
"      Tacklind J, Fink HA, Macdonald R, et al. Finasteride for benign prostatic hyperplasia. Cochrane Database Syst Rev 2010; :CD006015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/6\">",
"      Roehrborn CG, Nuckolls JG, Wei JT, et al. The benign prostatic hyperplasia registry and patient survey: study design, methods and patient baseline characteristics. BJU Int 2007; 100:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/7\">",
"      Hutchison A, Farmer R, Verhamme K, et al. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 2007; 51:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/8\">",
"      Black L, Naslund MJ, Gilbert TD Jr, et al. An examination of treatment patterns and costs of care among patients with benign prostatic hyperplasia. Am J Manag Care 2006; 12:S99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/9\">",
"      Roehrborn CG. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 2001; 58:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/10\">",
"      Andersson KE. Alpha1 adrenergic receptor blockade in the male lower urinary tract and other body systems. Scand J Urol Nephrol Suppl 1995; 168:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/11\">",
"      Lepor H. Alpha blockade for the treatment of benign prostatic hyperplasia. Urol Clin North Am 1995; 22:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/12\">",
"      Price DT, Schwinn DA, Lomasney JW, et al. Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. J Urol 1993; 150:546.",
"     </a>",
"    </li>",
"    <li>",
"     Westfall TC, Westfall DP. Adrenergic agonists and antagonists. In: The pharmacological basis of therapeutics, 11th ed, Brunton LL (Ed), McGraw-Hill, New York 2005. p.237.",
"    </li>",
"    <li>",
"     Rapaflo &reg; (silodosin) capsules US prescribing information November 2009. Watson Pharma Inc. Available at: file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=12598 (Accessed on October 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/15\">",
"      Lee M. Tamsulosin for the treatment of benign prostatic hypertrophy. Ann Pharmacother 2000; 34:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/16\">",
"      Lowe FC. Role of the newer alpha, -adrenergic-receptor antagonists in the treatment of benign prostatic hyperplasia-related lower urinary tract symptoms. Clin Ther 2004; 26:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/17\">",
"      Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992; 21:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/18\">",
"      Kyprianou N, Chon J, Benning CM. Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease. Prostate Suppl 2000; 9:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/19\">",
"      Chon JK, Borkowski A, Partin AW, et al. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia. J Urol 1999; 161:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/20\">",
"      Roehrborn CG. Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. Prostate Cancer Prostatic Dis 2006; 9:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/21\">",
"      MacDonald R, Wilt TJ, Howe RW. Doxazosin for treating lower urinary tract symptoms compatible with benign prostatic obstruction: a systematic review of efficacy and adverse effects. BJU Int 2004; 94:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/22\">",
"      MacDonald R, Wilt TJ. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology 2005; 66:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/23\">",
"      Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/24\">",
"      Garimella PS, Fink HA, Macdonald R, Wilt TJ. Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia. Cochrane Database Syst Rev 2009; :CD007360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/25\">",
"      Wilt TJ, Mac Donald R, Rutks I. Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev 2003; :CD002081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/26\">",
"      Roehrborn CG, Van Kerrebroeck P, Nordling J. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003; 92:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/27\">",
"      Marks LS, Gittelman MC, Hill LA, et al. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J Urol 2009; 181:2634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/28\">",
"      Schwinn DA, Price DT, Narayan P. alpha1-Adrenoceptor subtype selectivity and lower urinary tract symptoms. Mayo Clin Proc 2004; 79:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/29\">",
"      Nieminen T, Tammela TL, K&ouml;&ouml;bi T, K&auml;h&ouml;nen M. The effects of tamsulosin and sildenafil in separate and combined regimens on detailed hemodynamics in patients with benign prostatic enlargement. J Urol 2006; 176:2551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/30\">",
"      Giuliano F. Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 2006; 97 Suppl 2:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/31\">",
"      Imperato-McGinley J, Gautier T, Zirinsky K, et al. Prostate visualization studies in males homozygous and heterozygous for 5 alpha-reductase deficiency. J Clin Endocrinol Metab 1992; 75:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/32\">",
"      Zhu YS, Imperato-McGinley JL. 5alpha-reductase isozymes and androgen actions in the prostate. Ann N Y Acad Sci 2009; 1155:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/33\">",
"      Gormley GJ, Stoner E, Bruskewitz RC, et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/34\">",
"      McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998; 338:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/35\">",
"      Roehrborn CG, Bruskewitz R, Nickel JC, et al. Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol 2004; 171:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/36\">",
"      Glassman DT, Chon JK, Borkowski A, et al. Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia. Prostate 2001; 46:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/37\">",
"      Marks LS, Partin AW, Gormley GJ, et al. Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. J Urol 1997; 157:2171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/38\">",
"      Abrams P, Sch&auml;fer W, Tammela TL, et al. Improvement of pressure flow parameters with finasteride is greater in men with large prostates. Finasteride Urodynamics Study Group. J Urol 1999; 161:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/39\">",
"      Foley SJ, Soloman LZ, Wedderburn AW, et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol 2000; 163:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/40\">",
"      Miller MI, Puchner PJ. Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up. Urology 1998; 51:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/41\">",
"      Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/42\">",
"      Roehrborn CG, Nickel JC, Andriole GL, et al. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial. Urology 2011; 78:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/43\">",
"      Nickel JC, Gilling P, Tammela TL, et al. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 2011; 108:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/44\">",
"      Tenover JL, Pagano GA, Morton AS, et al. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Primary Care Investigator Study Group. Clin Ther 1997; 19:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/45\">",
"      Wessells H, Roy J, Bannow J, et al. Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003; 61:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/46\">",
"      Andriole GL, Guess HA, Epstein JI, et al. Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1998; 52:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/47\">",
"      Etzioni RD, Howlader N, Shaw PA, et al. Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. J Urol 2005; 174:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/48\">",
"      Matzkin H, Chen J, Weisman Y, et al. Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolism. Clin Endocrinol (Oxf) 1992; 37:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/49\">",
"      Jacobsen SJ, Cheetham TC, Haque R, et al. Association between 5-alpha reductase inhibition and risk of hip fracture. JAMA 2008; 300:1660.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm258529.htm (Accessed on June 13, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/51\">",
"      Jeong YB, Kwon KS, Kim SD, Kim HJ. Effect of discontinuation of 5alpha-reductase inhibitors on prostate volume and symptoms in men with BPH: a prospective study. Urology 2009; 73:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/52\">",
"      Roehrborn CG, Siami P, Barkin J, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/53\">",
"      Lepor H, Williford WO, Barry MJ, et al. The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. N Engl J Med 1996; 335:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/54\">",
"      Debruyne FM, Jardin A, Colloi D, et al. Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. Eur Urol 1998; 34:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/55\">",
"      Kirby RS, Roehrborn C, Boyle P, et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003; 61:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/56\">",
"      McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349:2387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/57\">",
"      Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/58\">",
"      Roehrborn CG, Andriole GL, Wilson TH, et al. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial. Eur Urol 2011; 59:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/59\">",
"      Kaplan SA, Roehrborn CG, Rovner ES, et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006; 296:2319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/60\">",
"      Lieber MM. Pharmacologic therapy for prostatism. Mayo Clin Proc 1998; 73:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/61\">",
"      Boyle P, Robertson C, Lowe F, Roehrborn C. Meta-analysis of clinical trials of permixon in the treatment of symptomatic benign prostatic hyperplasia. Urology 2000; 55:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/62\">",
"      Bent S, Kane C, Shinohara K, et al. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006; 354:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/63\">",
"      Wilt T, Ishani A, MacDonald R, et al. Beta-sitosterols for benign prostatic hyperplasia. Cochrane Database Syst Rev 2000; :CD001043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/64\">",
"      Wilt T, Mac Donald R, Ishani A, et al. Cernilton for benign prostatic hyperplasia. Cochrane Database Syst Rev 2000; :CD001042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/65\">",
"      Wilt T, Ishani A, Mac Donald R, et al. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst Rev 2002; :CD001044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/66\">",
"      Sairam K, Kulinskaya E, McNicholas TA, et al. Sildenafil influences lower urinary tract symptoms. BJU Int 2002; 90:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/67\">",
"      Liu L, Zheng S, Han P, Wei Q. Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Urology 2011; 77:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/68\">",
"      Oelke M, Giuliano F, Mirone V, et al. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012; 61:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/69\">",
"      Falahatkar S, Mokhtari G, Pourreza F, et al. Celecoxib for treatment of nocturia caused by benign prostatic hyperplasia: a prospective, randomized, double-blind, placebo-controlled study. Urology 2008; 72:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/70\">",
"      Brown CT, Yap T, Cromwell DA, et al. Self management for men with lower urinary tract symptoms: randomised controlled trial. BMJ 2007; 334:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/71\">",
"      Taub DA, Wei JT. The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Curr Urol Rep 2006; 7:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/31/8698/abstract/72\">",
"      Saigal CS, Movassaghi M, Pace J, et al. Economic evaluation of treatment strategies for benign prostatic hyperplasia--is medical therapy more costly in the long run? J Urol 2007; 177:1463.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6891 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.96.59.103-BD52B341D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_31_8698=[""].join("\n");
var outline_f8_31_8698=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS FOR THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Alpha-1-adrenergic antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Mechanism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Side effects and interactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      5-alpha-reductase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Mechanism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Discontinuation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Short-term efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Long-term efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Antimuscarinics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Herbal therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      MODIFICATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OTHER STRATEGIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      ECONOMIC CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6891\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6891|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/51/28477\" title=\"figure 1\">",
"      Prevalence of BPH with age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?13/22/13678\" title=\"figure 2\">",
"      Finasteride in BPH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/32/15872\" title=\"figure 3\">",
"      BPH combination therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6891|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/50/22317\" title=\"table 1\">",
"      International Prostate Symptom Score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/42/5805\" title=\"table 2\">",
"      Alpha-1 receptor antagonist",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41736?source=related_link\">",
"      Chemoprevention strategies in prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/53/36696?source=related_link\">",
"      Clinical manifestations and diagnostic evaluation of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=related_link\">",
"      Clinical presentation and diagnosis of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/18/33061?source=related_link\">",
"      Clinical use of saw palmetto",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/19/34104?source=related_link\">",
"      Epidemiology and pathogenesis of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11290?source=related_link\">",
"      Lower urinary tract symptoms in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=related_link\">",
"      Measurement of prostate specific antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20554?source=related_link\">",
"      Overview of herbal medicine and dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/51/28467?source=related_link\">",
"      Patient information: Benign prostatic hyperplasia (BPH) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/21/15698?source=related_link\">",
"      Patient information: Benign prostatic hyperplasia (enlarged prostate) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/7/40056?source=related_link\">",
"      Surgical and other invasive therapies of benign prostatic hyperplasia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_31_8699="Use of SCOOP system I";
var content_f8_31_8699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63083&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Patient management tips for the SCOOP transtracheal oxygen system - I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Phase",
"      </td>",
"      <td class=\"subtitle1\">",
"       Goal",
"      </td>",
"      <td class=\"subtitle1\">",
"       Management strategy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"2\">",
"       I",
"      </td>",
"      <td>",
"       Patient selection",
"      </td>",
"      <td>",
"       Select patients who are enthusiastic and desire to be active.The patient must be willing to assume responsibility for the catheter or have assistance from a significant other.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Patient orientation",
"      </td>",
"      <td>",
"       Reinforce verbal instructions by showing a videotape and giving the patient a booklet and article to review. Give the patient the phone number of another transtracheal patient to call to ask questions or ask the transtracheal patient to place the call.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Hoffman LA, Wesmiller SW.Transtracheal oxygen. In: Portable Oxygen Therapy: Including Oxygen Conserving Methodology, Tiep BL (Ed), Mount Kisco, NY, 1991.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_31_8699=[""].join("\n");
var outline_f8_31_8699=null;
var title_f8_31_8700="Types of moisturizers";
var content_f8_31_8700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72872&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Types of moisturizers",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Mechanism of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Indication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Occulsive",
"       </td>",
"       <td>",
"        Blocks transepidermal water loss",
"        <br/>",
"        Barrier",
"       </td>",
"       <td>",
"        Xerosis",
"        <br/>",
"        Atopic dermatitis",
"        <br/>",
"        Prevention of irritant contact dermatitis",
"       </td>",
"       <td>",
"        Petrolatum",
"        <br/>",
"        Zinc oxide",
"        <br/>",
"        Lanolin",
"        <br/>",
"        Mineral oil",
"        <br/>",
"        Silicones",
"       </td>",
"       <td>",
"        Messy, comedogenic",
"        <br/>",
"        Cosmetically unacceptable",
"        <br/>",
"        May cause folliculitis (mineral oil) or contact dermatitis (lanolin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Humectant",
"       </td>",
"       <td>",
"        Attracts water to stratum corneum",
"       </td>",
"       <td>",
"        Xerosis",
"        <br/>",
"        Icthyosis",
"       </td>",
"       <td>",
"        Urea",
"        <br/>",
"        Alpha hydroxy acids",
"        <br/>",
"        Glycerin",
"        <br/>",
"        Sorbital",
"        <br/>",
"        Lactic acid",
"       </td>",
"       <td>",
"        May cause irritation (urea, lactic acid)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emollient",
"       </td>",
"       <td>",
"        Smooths skin",
"       </td>",
"       <td>",
"        Decrease skin roughness",
"       </td>",
"       <td>",
"        Cholesterol",
"        <br/>",
"        Squalene",
"        <br/>",
"        Fatty acids",
"       </td>",
"       <td>",
"        Not always effective",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Replacement of deficiencies in \"raw materials\" of the intact stratum corneum",
"       </td>",
"       <td>",
"        Claims to replenish essential skin components",
"       </td>",
"       <td>",
"        Possibly skin rejuvenation",
"       </td>",
"       <td>",
"        <p>",
"         Ceramides, natural moisturizing factor",
"        </p>",
"       </td>",
"       <td>",
"        May improve skin moisturization and barrier function, but unproven",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Lynde, CW. Moisturizers: what they are and how they work. Skin Therapy Lett 2001; 6:3.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_31_8700=[""].join("\n");
var outline_f8_31_8700=null;
var title_f8_31_8701="Classification of syncope";
var content_f8_31_8701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F64301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F64301&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of syncope",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Reflex (neurally mediated) syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Vasovagal:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mediated by emotional distress: fear, pain, instrumentation, blood phobia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mediated by orthostatic stress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Situational:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cough, sneeze",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gastrointestinal stimulation (swallow, defecation, visceral pain)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Micturition (postmicturition)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Post-exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Postprandial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Others (eg, laughter, brass instrument playing, weightlifting)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Carotid sinus syncope",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Atypical forms (without apparent triggers and/or atypical presentation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Syncope due to orthostatic hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Primary autonomic failure:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pure autonomic failure, multiple system atrophy, Parkinson's disease with autonomic failure, Lewy body dementia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Secondary autonomic failure:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Diabetes, amyloidosis, uraemia, spincal cord injuries",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Drug-induced orthostatic hypotension:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alcohol, vasodilators, diuretics, phenotiazines, antidepressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Volume depletion:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemorrhage, diarrhoea, vomiting, etc",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiac syncope (cardiovascular)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Arrhythmia as primary cause:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Bradycardia:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Sinus node dysfunction (including bradycardia/tachycardia syndrome)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Atrioventricular conduction system disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Implanted device malfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Tachycardia:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Supraventricular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Ventricular (idiopathic, secondary to structural heart disease or to channelopathies)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_single\">",
"        Drug-induced bradycardia and tachyarrhythmias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Structural disease:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardiac: cardiac valvular disease, acute myocardial infarction/ischaemia, hypertrophic cardiomyopathy, cardiac masses (atrial myxoma, tumors, etc), pericardial disease/tamponade, congenital anomalies of coronary arteries, prosthetic valves dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Others: pulmonary embolus, acute aortic dissection, pulmonary hypertension",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: European Heart Rhythm Association (EHRA), Heart Failure Association (HFA), Heart Rhythm Society (HRS), et al. Guidelines for the diagnosis and management of syncope (version 2009): the Task Force for the Diagnosis and Management of Syncope of the European Society of Cardiology (ESC). Eur Heart J 2009; 30:2631. Copyright &copy; 2009 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_31_8701=[""].join("\n");
var outline_f8_31_8701=null;
var title_f8_31_8702="MCA peak velocity";
var content_f8_31_8702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76467&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    MCA peak velocity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 360px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     A: moderate to severe anemia; B: mild anemia; C: no anemia; MCA: middle cerebral artery; MOM: multiples of the median.",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Mari, G, for the Collaborative Group for Doppler Assessment of the Blood Velocity in Anemic Fetuses. Noninvasive diagnosis by Doppler ultrasonography of fetal anemia due to maternal red-cell alloimmunization. N Engl J Med 2000; 342:9.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_31_8702=[""].join("\n");
var outline_f8_31_8702=null;
var title_f8_31_8703="Rela incid immunodeficiency";
var content_f8_31_8703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F80845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F80845&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    Relative incidence of primary immunodeficiencies",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 431px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_31_8703=[""].join("\n");
var outline_f8_31_8703=null;
